

## CURRICULUM VITAE AND BIBLIOGRAPHY FORMAT

**DATE: October 16,2020**

**FULL NAME AND DEGREE/S:** Clifford J. Rosen, B.S, M.D.

**CURRENT ADMINISTRATIVE TITLE** (hospital and /or university if applicable): Director of Clinical and Translation Research, Maine Medical Center Research Institute, Portland, ME, Professor Medicine, Tufts University School of Medicine; Associate Editor- New England Journal of Medicine

**OFFICE ADDRESS** (Dept. or Division and Box No.): 81 Research Drive, Scarborough ME, 04074

**OFFICE PHONE NUMBER:** 207-396-8157

**E-MAIL ADDRESS:** Cjrofen@gmail.com

**FAX ADDRESS:** 207-396-8179

### **EDUCATION**

#### Undergraduate

1971 University of Maine, Orono, ME, B.S. with highest honors Biochemistry

#### Medical School and/or Graduate School

1975 State University of New York at Syracuse, Syracuse, NY, Upstate Medical Center, M.D.

### **POSTDOCTORAL TRAINING**

1975-1976 Internship, Berkshire Medical Center, Pittsfield, MA, Medicine

1976-1978 Residency, Berkshire Medical Center, (University of Massachusetts Medical Center) Internal Medicine, Pittsfield, MA

1978-1979 Chief Residency, Internal Medicine, Berkshire Medical Center, Pittsfield, MA

1982-1984 Endocrinology Fellowship, Dartmouth Hitchcock Medical Center, Hanover, NH

### **LICENSURE AND CERTIFICATION**

#### Medical Licensure

1979 State of Maine; Registration # 009817

1975-1979 State of Massachusetts

1993-2000 State of Massachusetts

2001-2008 Province of New Brunswick: Border License

#### State Certifications

1976 National Board of Medical Examiners

1978 American Board of Internal Medicine

1985 American Board of Internal Medicine, Subspecialty Endocrinology & Metabolism

### **ACADEMIC APPOINTMENTS**

1978-1979 Instructor in Medicine, University of Massachusetts, Worcester, MA

1982-1984 Instructor in Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH

1986-1988 Adjunct Associate Professor, School of Human Development, University of Maine, Orono, ME

1987-1993 Director of Diabetes Education Center, Eastern Maine Medical Center, Bangor, ME

1988-1990 Research Assistant Professor in Human Nutrition, School of Human Development, University of Maine, Orono, ME

1991-1995 Research Associate Professor in Human Nutrition, School of Human Development, University of Maine, Orono, ME

1992-1999 Clinical Associate Professor of Medicine, Tufts University School of Medicine, Boston MA  
 1993-1999 Associate Clinical Professor, Boston University School of Medicine, Boston, MA  
 1993-2007 Executive Director, Maine Center for Osteoporosis Research and Education, Bangor, ME  
 1996-1999 Research Professor of Nutrition and Food Sciences, University of Maine, Orono, ME  
 2000-2009 Professor of Nutrition, University of Maine, Orono, ME  
 1996-1998 Adjunct Scientist- The Jackson Laboratory  
 1997-2005 Adjunct Staff Scientist, The Jackson Laboratory, Bar Harbor, ME  
 1998-2004 Scientist- The Jackson Laboratory  
 2004-2007 Senior Scientist- The Jackson Laboratory  
 2005-2009 Senior Staff Scientist, The Jackson Laboratory, Bar Harbor, ME  
 2007-Present Senior Scientist, Maine Medical Center Research Institute, Scarborough, ME  
 2008-Present Director of Clinical and Translational Research, Maine Medical Center, Portland, ME  
 2009- Professor of Medicine, Tufts University School of Medicine, Boston, MA  
 2010- Visiting Scientist- The Buck Institute  
 2013- Adjunct Scientist; The Buck Institute Novato California  
 2015- 2020 Adjunct Professor- University of South Denmark (DU), Odense Denmark  
 2017- Faculty Tufts University School of Medicine CTSI  
 2018- Adjunct Faculty- Harvard School of Dental Medicine

### **HOSPITAL APPOINTMENTS**

1979-2001 Internal Medicine, Eastern Maine Medical Center and St. Joseph Hospital, Bangor, ME  
 1984-1994 Director of Endocrinology and Metabolism, St. Joseph Hospital, Bangor, ME  
 1986-1987 Chairman of Quality Assurance, St. Joseph Hospital, Bangor, ME  
 1987-1993 Director of Endocrinology and Metabolism, Eastern Maine Medical Center, Bangor, ME  
 1987-1998 Chief of Medicine, St. Joseph Hospital, Bangor, ME  
 1989-1995 Chairman of the Research Committee, Eastern Maine Medical Center, Bangor, ME  
 1991-1999 Special Scientific Staff, Boston City Hospital, BUMC, Boston, MA  
 1992-1995 Affiliate Staff, Maine Medical Center, Portland, ME  
 1993-1995 Special Scientific Staff, Boston University Medical Center, Boston, MA  
 1993-1999 Staff Endocrinologist, University Hospital: Boston, MA  
 1995-2007 Senior Staff Endocrinologist, Veterans Administration Hospital, Togus, Augusta, ME

### **AWARDS AND HONORS**

1987 Teacher of the Year, Family Practice Residency, Eastern Maine Medical Center, Bangor, ME  
 1989; 1995 Sponsor, Summer Research Fellowship, The Endocrine Society  
 1992-1994 Fellowship sponsor, visiting research associate, ECFMG Dr. Hung Zhao, Peoples Republic of China  
 1992 International Men of Achievement  
 1994 The Katherine Musgrave Maine Nutrition Council Public Service Award  
 1994 International Expert Panel, Detection and Interpretation of Bone Mass  
 1995 Endocrine Society: Mentor-Summer Student Fellowship  
 1995 Scientific Advisory Board: Biologic Effects of Light, Atlanta, GA  
 1996 Glenn Foundation Endocrinology and Aging Research Award  
 1996 Visiting Nutrition Professorship: National Dairy Council  
 1996-1997 Best Doctors in America: Northeast Region  
 1998 "Who's Who in the World"  
 1998-2000 "Who's Who in Medicine and Health Care"  
 2000 Distinguished Service to Medicine Award, Maine Medical Association  
 2001 2000 Outstanding Scientists of the 20th century  
 2001 Distinguished Career Alumni Award, University of Maine

2001-2002 President, American Society for Bone and Mineral Research  
 2001-2007 “Who’s Who in America”  
 2002 Great Teachers in Clinical Medicine Lecture Series: National Institutes of Health-  
 December 7  
 2008 Louis V. Avioli Memorial Lecture: Bone Marrow Fat: Neighbor or Nemesis. 30<sup>th</sup>  
 Annual ASBMR Official Scientific Meeting, Montreal, Canada, September 16, 2008  
 2009-2014 “Best Doctors in America”  
 2011-2015 American Board of Internal Medicine- Senior Examiner in Endocrinology, Metabolism  
 and Diabetes  
 2013 Larry Raisz Award for Distinguished Translational Research ASBMR  
 2016 William F. Neuman Award ASBMR outstanding and major scientific contributions in  
 the area of bone and mineral research and for contributions to associates and trainees in  
 teaching, research, and administration  
 2016 Genest Award Lecture-Canadian Endocrine Society

**HOSPITAL, MEDICAL SCHOOL, OR UNIVERSITY COMMITTEE ASSIGNMENTS:**

1989-1995 Chair, Eastern Maine Medical Center Research Committee  
 1996-2000 Chair, Evidence Based Review of Osteoporosis, McMaster University

**OTHER MAJOR COMMITTEE ASSIGNMENTS:**

1992; 1997 NIH (NIDDK): Metabolic Bone Disease (Ad hoc)  
 1993 International Society of Clinical Densitometry, Steering Committee  
 1993-1996 American Society of Bone and Mineral Research, Boy Frame Clinical Awards  
 Committee  
 1994-1998 American Society of Bone and Mineral Research, Public Affairs Committee  
 1995-1998 National Osteoporosis Foundation, Education Committee  
 1995-2008 Founding member and chair, New England Bone Club  
 1995-1998 Veterans Affairs, Merit Review, Endocrinology (Ad hoc)  
 1996-1998 NIH, SSS#7, SBIR  
 1997 Chair, National Osteoporosis Foundation, 4th International Meeting, Washington, DC  
 1997 Co-Chair, Third Annual Society of Clinical Densitometry, San Diego, CA  
 1997 Program Co-Chair, The NIH Conference on Growth Hormone-IGF Axis in Aging  
 1997-2007 American Society of Bone and Mineral Research Program Committee  
 1998 Chairperson, NIH-NICHD, Special Emphasis Panel-HD 37072, Peak Bone Mass  
 1998 (11/16) Chairperson, NIH OBM-2 SEP (ZRG-1)  
 1998 (Dec.) Chairperson, Special Study Section, NIH-NICHD, Behavioral Modifications and Peak  
 Bone Mass  
 1999 Chair, NIH-NICHD, Special Emphasis Panel, Bone Metabolism in Children  
 1999-2002 Permanent Member, NIH, Oral Biology and Medicine-2  
 1999 Program Committee Member, Third International Osteoporosis Program, Beijing, China  
 1999-2002 Chair, American Society of Bone and Mineral Research Advocacy Committee  
 2000-2008 Scientific Advisory Board, Yale Bone and Metabolic Bone Disease Core  
 2001 Chair, NIH-NICHD, Special Emphasis Panel, Bone Density in Children  
 2002 Chair, DSMB-NIH Combination Therapy Alendronate and low dose estrogen  
 2002-2004 Permanent Chair, NIH peer review, Skeletal Biology Development and Disease  
 2002-2004 Chair, NIH OBM-2 Study Section  
 2002 Growth Hormone and IGF Symposium, Program Committee  
 2002-2005 Endocrine Society, Meetings and Education Committee  
 2003 U.S. FDA, Endocrine and Metabolic Regulatory Panel  
 2003-2005 Maine Governor’s Panel on Health Care Reform, Legislative Confirmation with  
 Governor Nomination  
 2003 Chair, NIAMS, Special Emphasis Panel, LRP 5 and Bone

2003 Chair, DSMB, NIDDK, PTH in Glucocorticoid Induced Osteoporosis  
2003-2006 Chair, DSMB-NIAMS, Combined Estrogen and Alendronate Clinical Trial (PI Recker)  
2003-2007 Chair, DSMB-NICHD, Bone Density in Children Study (PI Winer-NICHD)  
2004-2006 Chair, DSMB-NIAMS, Nitroglycerin for Osteoporosis (PI Wimalawansa)  
2006 (12/11) Chair, NIAMS, Special Emphasis Panel, Clinical Trial Outcomes-Surrogate Indicators  
2006 (12/16) Chair, National Cancer Institute of Canada, Program Project Review  
2007 NIH-NRSA, ZRG4 GRM(07)L (Ad hoc)  
2007 Committee person, DSMB-NIAMS, PTH + Phosphate for Osteoporosis (PI Heaney)  
2007 DSMB Committee person and Chair, NIA, Calcium and vitamin D for osteoporosis (PI Heaney)  
2008 Co-Chair, R13 NIH Conference on Bone Fat and Brain, ASBMR April 2009  
2008 – 2011 Endocrine Society Annual Meeting Committee Member  
2008-2014 NIA: Member CTAP Clinical Trials Advisory Panel  
2010-2013 IOM Vitamin D committees  
2011-2017 Chair- NIAMS Clinical Trials Review Panel (AMSCT)-  
2011 Editorial Board Member- NIH MOSS Study Section  
2011-2014 New England Bone Club- Chair  
2012-2013 IOM CTSA Review Committee  
2013- NIDDK DSMB Member- Grade Trial-Chairperson  
2013- NIAMS Chair: Ad hoc Review Panel on Clinical Instruments for measuring outcome  
2013 NIAMS Anabolic Bone Roundtable  
2014- Chair External Advisory Committee –CcaTS-Mayo Clinic CTSA  
2014- NIH ODS- Vitamin D Moving Toward Evidence in Primary Care- Chairperson  
2015- NIA: Special Study Section Chair- Mitochondrial Biology of Aging  
2015- International Bone Marrow Adiposity Meetings 1, 2 France, and Holland  
2015 NIH-NICHD Conference on Peak Bone Mass- November 14,15, 2015  
2017 NIA- Gerosciences Seminar- NIH-Natcher Auditorium February 1

**TRAINING OF GRADUATE STUDENTS/POST DOCTORAL** (list present and past)

July 2018- Current Li Tian- Sichuan University- Postdoc  
October 2018-Current Yosta Vegting- University of Amsterdam- PhD  
April 2017- Current Makoto Fujiwara MD- University of Osaka-Post doc  
April 2017- January 2018 A.G. Veldhuis-Vlag MD PhD- Amsterdam University  
October 2015 – Present Elizabeth Rendina-Ruedy PhD/ Oklahoma State University,  
Bone-Fat Interaction  
October 2010- 2018 Katie Bishop PhD- University of Wisconsin  
October 2015- Present Carolina Figueroa- PhD student University of Maine GSBSE  
October 2010- 2017 David Maridas – PhD University of Maine GSBSE  
October 2009-2015 Casey Doucette PhD- University of Maine  
October 2011-2015 Anyonya Guntur PhD- University of Texas San Antonio  
May 2010 – September 2014 Katherine J. Motyl, PhD/ Michigan State University, Bone loss  
from the atypical antipsychotic (AA) Risperidone  
June 2014 – September 2015 Michaela Reagan, PhD/Tufts University, Multiple Myeloma and  
Bone Metastasis  
January 2008-September 2011 Masa Kawai MD- Osaka University  
October 2010 – April 2012 Ann E. Maloney, MD/University of Vermont, Skeletal and  
Metabolic Impact of the Antipsychotic Risperidone on  
Adolescent Youth  
2010 – 2015 Angeli Sharma, MD State University of New York-Downstate,  
HIV and Bone Density  
2003-2007- Cheryl Ackert-Bicknell- University of Maine PhD-PPARG and  
Bone

## **TEACHING RESPONSIBILITIES**

May 23, 1995	McMaster University Medical Center, Visiting Professor, Academic Half Day, Hamilton ONT
December 1-7, 1995	Mayo Clinic and Medical School, Visiting professor
May 4-6, 1996	University of Texas Galveston, Visiting professor in orthopedic research
December 11-13, 1996	Western Reserve University Hospitals, Visiting Professor Case
April 30-May 2, 1997	University of Arizona Visiting Professor
October 15, 1997	Yale University Medical Center, Bayer Visiting Professor
Oct 20- Nov 20 2011	Visiting professor UCSF, Department of Epidemiology and Biostatistics.
May 5, 2013	Visiting Professor- University of Alabama Birmingham
May 13, 2013	Visiting Professor- University of Texas Southwestern- Dallas Texas
January 20,2014	Visiting Professor Rush Medical School, Chicago, Illinois
April 2, 2014	Visiting Professor Cornell Medical College
November 19,2014	Visiting Professor- Harvard Medical and Dental School
November 2014	Visiting Professor- Endocrine Division- Mass General Hospital
June 2015	Visiting Professor- University of Chile- Santiago
June 2015-	Visiting Professor- University of South Denmark, Odense Denmark
September 2015	SUNY Upstate University- Visiting Professor
March 2016	Visiting Professor- Brigham and Women's Hospital Boston, MA
April 2016	Visiting Professor- Dalhousie University- Halifax, Nova Scotia

## **PROFESSIONAL SOCIETIES**

1979-1987	Member, Physicians for Social Responsibility
1988-Present	Member, The Endocrine Society
1989-Present	Member, American Federation of Clinical Research
1989-Present	Member, American Society of Bone and Mineral Research
1990-1992	Member, Scientific Advisory Council, Institute for Cellular Research, Bangor, ME
1992-1995	Founding Member and Treasurer, International Society of Clinical Densitometry
1993-1998	National Osteoporosis Foundation
1993	National Faculty Member, Core Content Review of Family Medicine
1993	Member, National Health Policy Advisory Council
1994	Founding Member, Annual Winter Meeting, Bone Biology and Clinical Medicine, Sugarloaf USA
1994; 1997	Program Chairman, First/Third Annual Meeting, Society of Clinical Densitometry
1994-Present	Member, American Academy for the Advancement of Science
1995-2008	Founding Member, New England Bone Club
1995-1999	Member, National Osteoporosis Foundation, Scientific Advisory Board
1995-2007	Co-Chair, American Society of Bone and Mineral Research, Skeletal Models of Aging Workshop
1995-2007	Program Tri-Chair, American Society of Bone Mineral Research, Skeletal Aging
1995-Present	Member, New York Academy of Sciences
1996-2000	Boy Frame Working Group, American Society of Bone Mineral Research, Program Chair
1999	Chair, Atlantic Endocrine Society, Bar Harbor, ME
1997-2001	Chair, Advocacy Committee, American Society of Bone and Mineral Research
2002-2003	President, American Society of Bone and Mineral Research

2002-2004	Chairperson, NIH Peer Review Study Section, SBBD Skeletal Biology Development and Disease
2003-2011	Gordon Conference Contributor: IGFs, Ventura, CA
2003-2004	Executive Board, American Society of Bone and Mineral Research
2005-2008	Endocrine Society, Committee Member and Instructor, CEU and Board Review
2006-2008	Council Board Member, Maine Institute for Human Genetics
2006-	Member, FDA Endocrinologic and Metabolic Advisory Board
2007-2008	Chairperson, U.S. FDA Reproductive Medicine Advisory Committee
2007-2010	Member, NIAMS Scientific Advisory Council
2008-2111	Member, Annual Program Committee Member, Endocrine Society
2010-2012	Institute of Medicine Committee Member- Calcium and Vitamin D
2012-2013	Institute of Medicine Committee Member- NCATS/CTSA Review
2014-	Committee Reviewer- Biology of Aging Program- National Institutes of Health-NIA
2015-2017	NIDDK Editorial Reviewer
2016-2020	Endocrine Society Council Member
2018-2022	NIA Advisory Council
2010-2017	Chair, NIAMS Clinical Trials Peer Review Study Section
2018	Gordon Conference Bones and Teeth-Galveston, Tx
2018	Gordon Conference: Molecular Studies of Motion and Energy- Plymouth NH-

### **OFFICE AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES**

1992-1997	American Institute of Biological Sciences NASA: Physiology and Countermeasures (Ad hoc)
1997	Swiss Science Foundation (Ad hoc)
2002-2006	National Osteoporosis Foundation (Ad hoc)

### **MAJOR RESEARCH INTERESTS**

Dr. Rosen's research interests are translational and focused on studying mesenchymal stem cell fate with particular reference to the switch between pre-adipocytes and pre-osteoblasts. A central theme of his laboratory is lineage allocation, its biochemical determinants and its alterations in osteoporosis and obesity. He oversees whole body and cell phenotyping related to metabolic function in his physiology core facility for mouse phenotyping. He directs the NNE-CTR which funded by NIH supports infrastructure support for clinical research in Northern New England. He plays a lead role in clinical trials that translate basic science findings on bone biology and metabolism to the clinical arena, including the D2d study on vitamin D supplementation to prevent T2d.

**RESEARCH SUPPORT** (present and brief summary of the past three years): Continuous NIH Funding for 25 years.

*Grant title:* Interdisciplinary study of marrow adiposity Mineral metabolism and bone remodeling

*Funding Source:* NIH-NIDDK R24

*Amount:* \$209, 169 (current annual direct costs only)

*Period:* 9/1/2015-8/31/2020

*Role:* Contact PI on Multiple PI grant

*Grant title:* Determination of the mechanisms by Which IGF1BP-2 stimulates bone remodeling

*Funding Source:* NIH

*Amount:* \$150,774 (current annual direct costs only)

*Period:* 8/1/2011 – 7/31/2017

*Role:* Contact PI on Multiple PI grant

*Grant title:* Administrative supplement to define biologic sex determinants between male and female bone cells

*Funding Source:* NIH-NIAMS

*Amount:* \$32,051 (current annual direct costs only)

*Period:* 8/1/2015-7/31/2017

*Role:* Contact PI on Multiple PI Grant

*Grant title:* Vitamin D for type 2 Diabetes Study (D2d trial)

*Funding Source:* NIH/Tufts

*Amount:* Salary only

*Period:* 6/1/2013 – 5/31/2018

*Role:* Co-Investigator and Executive Steering Committee for D2d

*Grant title:* COBRE in Stem Cell Biology and Regenerative Medicine

*Funding Source:* NIH

*Amount:* \$76,350 (current annual direct costs only)

*Period:* 9/1/2013 – 6/30/2018

*Role:* Core Leader, Physiology Core,

*Grant title:* Osteoblastic resorption and IRS signaling

*Funding Source:* NIH-NIAMS

*Amount:* \$125,000 (current annual direct costs only)

*Period:* 4/1/2015-9/30/2017

*Role:* PI

*Grant title:* Central Role for Osteocytes in Integration of Endocrine Signals During Growth

*Funding Source:* NIH/NYU

*Amount:* \$23,332 (current annual direct costs only)

*Period:* 7/9/2014-5/31/2017

*Role:* Co-Investigator

*Grant title:* Genetic Analysis of Bone Strength

*Funding Source:* NIH/UVA

*Amount:* \$39,179 (current annual direct costs)

*Period:* 4/1/2016-3/31/2021

*Role:* PI on multiple PI with Dr. Charles Farber

*Grant Title:* PTH resistance and marrow adipogenesis

*Funding source:* NIH NIDDK RO1

*Amount* 395,000\$

*Period* 2017-2021

*Role* Multiple PI with Roland Baron DDS HSDM

*Grant Title: Cellular mechanisms of PTH1R activation with osteoporosis treatment*  
*Funding source NIH NIAMS R21*  
*Amount 375,000\$*  
*Period 7/17-3/31/19*  
*Role PI*

*Grant Title: Northern New England Clinical and Translational Research Network*  
*Funding Source NIGMS U54*  
*Amount 20,000,000 \$*  
*Role: 2017-2022 PI-*

*Grant Title: COBRE Mesenchymal and Neural Networks*  
*Funding Source- NIGMS*  
*Amount: \$11,000,000*  
*2017-2022*  
*Role: Director of Physiology Core and Executive Committee Co-Director*

*Grant Title: FSH as an Aging Hormone*  
*Funding source-NIA*  
*Amount 12,000,000*  
*2019-2024*  
*Role: Multi-PI and Aim 3 Project Director-*  
*Collaborative with Mt.Sinai Medical Center, NYC*

#### **EDITORIAL BOARDS AND ACTIVITY**

1993-1998	Editor in Chief J Clinical Densitometry
1996-2000	Editorial Board J Clin Endocrinol Metab
1997-2002	Editorial Board J Bone Mineral Research
2003-2008	Associate Editor J Bone Mineral Research
2009-2012	Associate Editor J Clin Endocrinol Metab
2013-2014	Senior Associate Editor- J Bone Min Research
2007-2014	Editor in Chief- Primer in Metabolic Bone Disease
2010-2014	Associate Editor- Aging Cell
2014-	Associate Editor- New England Journal of Medicine
2015-	Associate Editor- Endocrine Reviews
2016-	Board of Reviewing Editors-eLife



**\*BIBLIOGRAPHY 519 papers on PubMed, H factor 118; 59,700 citations**

*a) Refereed (i.e., peer-reviewed) research papers*

1. Douglas GW, Buck LL, and Rosen CJ. 1979. Liver abscess caused by *Haemophilus paraphrohaemolyticus*. *J Clin Microbiol* 9:299-300.
2. Rosen CJ, and Hasler GR. 1980. Pituitary metastatic disease: report of a case and review of the literature. *J Maine Med Assoc* 71:238-240.
3. Musgrave KO, Giambalvo L, Leclerc HL, Cook RA, and Rosen CJ. 1989. Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake. *J Am Diet Assoc* 89:1484-1488.
4. Davee AM, Rosen CJ, and Adler RA. 1990. Exercise patterns and trabecular bone density in college women. *J Bone Miner Res* 5:245-250.
5. Donahue LR, Hunter SJ, Sherblom AP, and Rosen C. 1990. Age-related changes in serum insulin-like growth factor-binding proteins in women. *J Clin Endocrinol Metab* 71:575-579.
6. Rosen CJ, Usiskin K, Owens M, Barlaschini CO, Belsky M, and Adler RA. 1990. T lymphocyte surface antigen markers in osteoporosis. *J Bone Miner Res* 5:851-855.
7. Hunter SJ, Rosen CJ, and Gay CV. 1991. In vitro resorptive activity of isolated chick osteoclasts: effects of carbonic anhydrase inhibition. *J Bone Miner Res* 6:61-66.
8. Rosen CJ, and Adler RA. 1992. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. *J Clin Endocrinol Metab* 75:1531-1534.
9. Rosen CJ, Donahue LR, Hunter S, Holick M, Kavookjian H, Kirschenbaum A, Mohan S, and Baylink DJ. 1992. The 24/25-kDa serum insulin-like growth factor-binding protein is increased in elderly women with hip and spine fractures. *J Clin Endocrinol Metab* 74:24-27.
10. Rosen CJ, Segal H, Hartz CE, Mroz F, and Carlton E. 1992. Primary hyperparathyroidism in an elderly patient with multiple myeloma. *J Am Geriatr Soc* 40:703-705.
11. Bing-You RG, Denis MC, and Rosen CJ. 1993. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. *Calcif Tissue Int* 52:183-187.
12. Hobbs CJ, Plymate SR, Rosen CJ, and Adler RA. 1993. Testosterone administration increases insulin-like growth factor-I levels in normal men. *J Clin Endocrinol Metab* 77:776-779.
13. Scharla SH, Strong DD, Rosen C, Mohan S, Holick M, Baylink DJ, and Linkhart TA. 1993. 1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. *J Clin Endocrinol Metab* 77:1190-1197.
14. Poehlman ET, Rosen CJ, and Copeland KC. 1994. The influence of endurance training on insulin-like growth factor-1 in older individuals. *Metabolism* 43:1401-1405.
15. Rosen CJ, Holick MF, and Millard PS. 1994. Premature graying of hair is a risk marker for osteopenia. *J Clin Endocrinol Metab* 79:854-857.
16. Rosen CJ, Morrison A, Zhou H, Storm D, Hunter SJ, Musgrave K, Chen T, Wei W, and Holick MF. 1994. Elderly women in northern New England exhibit seasonal changes in bone mineral density and calcitropic hormones. *Bone Miner* 25:83-92.
17. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, and Baker S. 1994. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. *Arterioscler Thromb* 14:1586-1593.
18. Rosen HN, Tollin S, Balena R, Middlebrooks VL, Beamer WG, Donohue LR, Rosen C, Turner A, Holick M, and Greenspan SL. 1995. Differentiating between orchietomized rats and controls using measurements of trabecular bone density: a comparison among DXA, histomorphometry, and peripheral quantitative computerized tomography. *Calcif Tissue Int* 57:35-39.
19. Beamer WG, Donahue LR, Rosen CJ, and Baylink DJ. 1996. Genetic variability in adult bone density among inbred strains of mice. *Bone* 18:397-403.

20. Plymate SR, Rosen CJ, Paulsen CA, Ware JL, Chen J, Vessella RE, and Birnbaum RS. 1996. Proteolysis of insulin-like growth factor-binding protein-3 in the male reproductive tract. *J Clin Endocrinol Metab* 81:618-624.
21. Prior RL, Crim MC, Castaneda C, Lammi-Keefe C, Dawson-Hughes B, Rosen CJ, and Spindler AA. 1996. Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. *J Am Coll Nutr* 15:237-247.
22. Rall LC, Rosen CJ, Dolnikowski G, Hartman WJ, Lundgren N, Abad LW, Dinarello CA, and Roubenoff R. 1996. Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. *Arthritis Rheum* 39:1115-1124.
23. Chesnut CH 3<sup>rd</sup>, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr., Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ. 1997. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. *Am J Med* 102:29-37.
24. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, and Bilezikian JP. 1997. Insulin-like growth factor-I in men with idiopathic osteoporosis. *J Clin Endocrinol Metab* 82:2799-2805.
25. Poehlman ET, Toth MJ, Ades PA, and Rosen CJ. 1997. Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. *Eur J Clin Invest* 27:322-326.
26. Poehlman ET, Toth MJ, Goran MI, Carpenter WH, Newhouse P, and Rosen CJ. 1997. Daily energy expenditure in free-living non-institutionalized Alzheimer's patients: a doubly labeled water study. *Neurology* 48:997-1002.
27. Rosen CJ, Chesnut CH 3<sup>rd</sup>, and Mallinak NJ. 1997. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. *J Clin Endocrinol Metab* 82:1904-1910.
28. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, and Baylink DJ. 1997. Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. *Bone* 21:217-223.
29. Rosen CJ, Vereault D, Steffens C, Cheleuitte D, and Glowacki J. 1997. Effects of age and estrogen status on the skeletal IGF regulatory system. Studies with human marrow. *Endocrine* 7:77-80.
30. Devine A, Rosen C, Mohan S, Baylink D, and Prince RL. 1998. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. *Am J Clin Nutr* 68:200-206.
31. Dimai HP, Linkhart TA, Linkhart SG, Donahue LR, Beamer WG, Rosen CJ, Farley JR, and Baylink DJ. 1998. Alkaline phosphatase levels and osteoprogenitor cell numbers suggest bone formation may contribute to peak bone density differences between two inbred strains of mice. *Bone* 22:211-216.
32. Kessenich CR, Guyatt GH, and Rosen CJ. 1998. Health-related quality of life and participation in osteoporosis clinical trials. *Calcif Tissue Int* 62:189-192.
33. Kiel DP, Puhl J, Rosen CJ, Berg K, Murphy JB, and MacLean DB. 1998. Lack of an association between insulin-like growth factor-I and body composition, muscle strength, physical performance or self-reported mobility among older persons with functional limitations. *J Am Geriatr Soc* 46:822-828.
34. Klein GL, Wolf SE, Langman CB, Rosen CJ, Mohan S, Keenan BS, Matin S, Steffen C, Nicolai M, Sailer DE, Herndon DN. 1998. Effects of therapy with recombinant human growth hormone on insulin-like growth factor system components and serum levels of biochemical markers of bone formation in children after severe burn injury. *J Clin Endocrinol Metab* 83:21-24.
35. Kurland ES, Chan FK, Rosen CJ, and Bilezikian JP. 1998. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. *J Clin Endocrinol Metab* 83:2576-2579.

36. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, and Kiel DP. 1998. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. *J Clin Endocrinol Metab* 83:4257-4262.
37. Patton CL, Millard PS, Kessenich CR, Storm D, Kinnicutt E, and Rosen CJ. 1998. Screening calcaneal ultrasound and risk factors for osteoporosis among lesbians and heterosexual women. *J Womens Health* 7:909-915.
38. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, and Bilezikian JP. 1998. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. *J Clin Endocrinol Metab* 83:2286-2290.
39. Roubenoff R, Rall LC, Veldhuis JD, Kehayias JJ, Rosen C, Nicolson M, Lundgren N, and Reichlin S. 1998. The relationship between growth hormone kinetics and sarcopenia in postmenopausal women: the role of fat mass and leptin. *J Clin Endocrinol Metab* 83:1502-1506.
40. Storm D, Eslin R, Porter ES, Musgrave K, Vereault D, Patton C, Kessenich C, Mohan S, Chen T, Holick MF, Rosen CJ. 1998. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. *J Clin Endocrinol Metab* 83:3817-3825.
41. Beamer WG, Shultz KL, Churchill GA, Frankel WN, Baylink DJ, Rosen CJ, and Donahue LR. 1999. Quantitative trait loci for bone density in C57BL/6J and CAST/EiJ inbred mice. *Mamm Genome* 10:1043-1049.
42. Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, Rosen CJ, Kessenich CR, Stock JL, Overfor J, Miller PD, Erickson AL, McClung MR, McClung BL, Griffith LE, Ioannidis G. 1999. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. *Osteoporos Int* 10:207-213.
43. Heaney RP, McCarron DA, Dawson-Hughes B, Oparil S, Berga SL, Stern JS, Barr SI, and Rosen CJ. 1999. Dietary changes favorably affect bone remodeling in older adults. *J Am Diet Assoc* 99:1228-1233.
44. Jiang Y, Zhao J, Rosen C, Geusens P, and Genant HK. 1999. Perspectives on bone mechanical properties and adaptive response to mechanical challenge. *J Clin Densitom* 2:423-433.
45. Kodama Y, Dimai HP, Wergedal J, Sheng M, Malpe R, Kutilek S, Beamer W, Donahue LR, Rosen C, Baylink DJ, Farley J. 1999. Cortical tibial bone volume in two strains of mice: effects of sciatic neurectomy and genetic regulation of bone response to mechanical loading. *Bone* 25:183-190.
46. Linkhart TA, Linkhart SG, Kodama Y, Farley JR, Dimai HP, Wright KR, Wergedal JE, Sheng M, Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. 1999. Osteoclast formation in bone marrow cultures from two inbred strains of mice with different bone densities. *J Bone Miner Res* 14:39-46.
47. Niu T, Chen C, Cordell H, Yang J, Wang B, Wang Z, Fang Z, Schork NJ, Rosen CJ, and Xu X. 1999. A genome-wide scan for loci linked to forearm bone mineral density. *Hum Genet* 104:226-233.
48. Sheng MH, Baylink DJ, Beamer WG, Donahue LR, Rosen CJ, Lau KH, and Wergedal JE. 1999. Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ (high-density) than C57BL/6J (low-density) mice during growth. *Bone* 25:421-429.
49. Sites CK, Tischler MD, Rosen CJ, O'Connell M, Niggel J, and Ashikaga T. 1999. Effect of short-term medroxyprogesterone acetate on left ventricular mass: role of insulin-like growth factor-1. *Metabolism* 48:1328-1331.
50. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. 1999. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab* 84:2647-2653.

51. Beamer WG, Rosen CJ, Bronson RT, Gu W, Donahue LR, Baylink DJ, Richardson CC, Crawford GC, and Barker JE. 2000. Spontaneous fracture (sfx): a mouse genetic model of defective peripubertal bone formation. *Bone* 27:619-626.
52. Goodman-Gruen D, Barrett-Connor E, and Rosen C. 2000. IGF-1 and ischemic heart disease in older people. *J Am Geriatr Soc* 48:860-861.
53. Haden ST, Glowacki J, Hurwitz S, Rosen C, and LeBoff MS. 2000. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. *Calcif Tissue Int* 66:414-418.
54. Kodama Y, Miyakoshi N, Linkhart TA, Wergedal J, Srivastava A, Beamer W, Donahue LR, Rosen C, Baylink DJ, and Farley J. 2000. Effects of dietary calcium depletion and repletion on dynamic determinants of tibial bone volume in two inbred strains of mice. *Bone* 27:445-452.
55. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, and Bilezikian JP. 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. *J Clin Endocrinol Metab* 85:3069-3076.
56. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, and Rosen CJ. 2000. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. *J Clin Endocrinol Metab* 85:2129-2134.
57. Rosen CJ, Churchill GA, Donahue LR, Shultz KL, Burgess JK, Powell DR, Ackert C, and Beamer WG. 2000. Mapping quantitative trait loci for serum insulin-like growth factor-1 levels in mice. *Bone* 27:521-528.
58. Snow CM, Rosen CJ, and Robinson TL. 2000. Serum IGF-I is higher in gymnasts than runners and predicts bone and lean mass. *Med Sci Sports Exerc* 32:1902-1907.
59. Toth MJ, Tchernof A, Rosen CJ, Matthews DE, and Poehlman ET. 2000. Regulation of protein metabolism in middle-aged, premenopausal women: roles of adiposity and estradiol. *J Clin Endocrinol Metab* 85:1382-1387.
60. Turner CH, Hsieh YF, Muller R, Bouxsein ML, Baylink DJ, Rosen CJ, Grynblas MD, Donahue LR, and Beamer WG. 2000. Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. *J Bone Miner Res* 15:1126-1131.
61. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. 2000. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 67:277-285.
62. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagen JA, Clemens TL. 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. *Endocrinology* 141:2674-2682.
63. Beamer WG, Shultz KL, Donahue LR, Churchill GA, Sen S, Wergedal JR, Baylink DJ, and Rosen CJ. 2001. Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ inbred strains of mice. *J Bone Miner Res* 16:1195-1206.
64. Bikle D, Majumdar S, Laib A, Powell-Braxton L, Rosen C, Beamer W, Nauman E, Leary C, and Halloran B. 2001. The skeletal structure of insulin-like growth factor I-deficient mice. *J Bone Miner Res* 16:2320-2329.
65. Drake WM, McClung M, Njeh CF, Genant HK, Rosen C, Watts N, and Kendler DL. 2001. Multisite bone ultrasound measurement on North American female reference population. *J Clin Densitom* 4:239-248.
66. Hennessey JV, Chromiak JA, DellaVentura S, Reinert SE, Puhl J, Kiel DP, Rosen CJ, Vandenberg H, and MacLean DB. 2001. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. *J Am Geriatr Soc* 49:852-858.
67. Milne M, Quail JM, Rosen CJ, and Baran DT. 2001. Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. *J Cell Biochem* 81:229-240.
68. Richman C, Kutilek S, Miyakoshi N, Srivastava AK, Beamer WG, Donahue LR, Rosen CJ, Wergedal JE, Baylink DJ, and Mohan S. 2001. Postnatal and pubertal skeletal changes contribute

- predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice. *J Bone Miner Res* 16:386-397.
69. Turner CH, Hsieh YF, Muller R, Bouxsein ML, Rosen CJ, McCrann ME, Donahue LR, and Beamer WG. 2001. Variation in bone biomechanical properties, microstructure, and density in BXH recombinant inbred mice. *J Bone Miner Res* 16:206-213.
  70. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, and Halloran BP. 2002. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. *J Bone Miner Res* 17:1570-1578.
  71. Boonen S, Rosen CJ, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vanderschueren D, Geusens P. 2002. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. *J Clin Endocrinol Metab* 87:1593-1599.
  72. Bouxsein ML, Rosen CJ, Turner CH, Ackert CL, Shultz KL, Donahue LR, Churchill G, Adamo ML, Powell DR, Turner RT, Muller R, Beamer WG. 2002. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. *J Bone Miner Res* 17:570-579.
  73. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, and Rosen CJ. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev* 23:570-578.
  74. Gordon CM, Goodman E, Emans SJ, Grace E, Becker KA, Rosen CJ, Gundberg CM, and Leboff MS. 2002. Physiologic regulators of bone turnover in young women with anorexia nervosa. *J Pediatr* 141:64-70.
  75. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, and LeBoff MS. 2002. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. *J Clin Endocrinol Metab* 87:4935-4941.
  76. Gu W, Li X, Lau KH, Edderkaoui B, Donahue LR, Rosen CJ, Beamer WG, Shultz KL, Srivastava A, Mohan S, Baylink DJ. 2002. Gene expression between a congenic strain that contains a quantitative trait locus of high bone density from CAST/EiJ and its wild-type strain C57BL/6J. *Funct Integr Genomics* 1:375-386.
  77. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, and Rosen C. 2002. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. *Endocrinol Metab Clin North Am* 31:659-679, xii.
  78. Hayman SR, Drake WM, Kendler DL, Olszynski WP, Webber CE, Rosen CJ, Genant HK, Orwoll ES, Pickard LE, and Adachi JD. 2002. North American male reference population for speed of sound in bone at multiple skeletal sites. *J Clin Densitom* 5:63-71.
  79. Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, Wilson PW, Visser M, Langlois JA, Mohan S, Kiel DP. 2002. Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women. *Calcif Tissue Int* 71:323-328.
  80. Pratipanawatr T, Pratipanawatr W, Rosen CJ, Berria R, Bajaj M, Cusi K, Mandarino L, Kashyap S, Belfort R, and DeFronzo RA. 2002. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. *Am J Physiol Endocrinol Metab* 282:E1360-1368.
  81. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, and Rosen CJ. 2002. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. *J Clin Endocrinol Metab* 87:4273-4279.
  82. Schoen RE, Schragin J, Weissfeld JL, Thaete FL, Evans RW, Rosen CJ, and Kuller LH. 2002. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. *Cancer Epidemiol Biomarkers Prev* 11:581-586.
  83. Tuckerman K, Hofmaster P, Rosen CJ, and Turi M. 2002. Bone density in ambulatory and immobile children. *J Clin Densitom* 5:327-334.
  84. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. 2002. Circulating levels of IGF-1 directly regulate bone growth and density. *J Clin Invest* 110:771-781.

85. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. 2002. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. *J Biol Chem* 277:44005-44012.
86. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, and Rosen CJ. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Engl J Med* 349:1207-1215.
87. Donahue LR, Chang B, Mohan S, Miyakoshi N, Wergedal JE, Baylink DJ, Hawes NL, Rosen CJ, Ward-Bailey P, Zheng QY, Bronson RT, Johnson KR, Davison MT. 2003. A missense mutation in the mouse Col2a1 gene causes spondyloepiphyseal dysplasia congenita, hearing loss, and retinoschisis. *J Bone Miner Res* 18:1612-1621.
88. Drake WM, Kendler DL, Rosen CJ, and Orwoll ES. 2003. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. *J Clin Endocrinol Metab* 88:5759-5765.
89. Koller DL, Schriefer J, Sun Q, Shultz KL, Donahue LR, Rosen CJ, Foroud T, Beamer WG, and Turner CH. 2003. Genetic effects for femoral biomechanics, structure, and density in C57BL/6J and C3H/HeJ inbred mouse strains. *J Bone Miner Res* 18:1758-1765.
90. Li Y, Iida K, O'Neil J, Zhang P, Li S, Frank A, Gabai A, Zambito F, Liang SH, Rosen CJ, Cavener DR. 2003. PERK eIF2alpha kinase regulates neonatal growth by controlling the expression of circulating insulin-like growth factor-I derived from the liver. *Endocrinology* 144:3505-3513.
91. Sakata T, Halloran BP, Elalieh HZ, Munson SJ, Rudner L, Venton L, Ginzinger D, Rosen CJ, and Bikle DD. 2003. Skeletal unloading induces resistance to insulin-like growth factor I on bone formation. *Bone* 32:669-680.
92. Shultz KL, Donahue LR, Bouxsein ML, Baylink DJ, Rosen CJ, and Beamer WG. 2003. Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral bone mineral density. *J Bone Miner Res* 18:175-185.
93. Silha JV, Mishra S, Rosen CJ, Beamer WG, Turner RT, Powell DR, and Murphy LJ. 2003. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. *J Bone Miner Res* 18:1834-1841.
94. Solomon DH, Connelly MT, Rosen CJ, Dawson-Hughes B, Kiel DP, Greenspan SL, Leib ES, Holick M, Miguel AH, and Finkelstein JS. 2003. Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England. *Osteoporos Int* 14:123-129.
95. Turner CH, Sun Q, Schriefer J, Pitner N, Price R, Bouxsein ML, Rosen CJ, Donahue LR, Shultz KL, and Beamer WG. 2003. Congenic mice reveal sex-specific genetic regulation of femoral structure and strength. *Calcif Tissue Int* 73:297-303.
96. Zhang M, Faugere MC, Malluche H, Rosen CJ, Chernausk SD, and Clemens TL. 2003. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. *J Bone Miner Res* 18:836-843.
97. Bouxsein ML, Uchiyama T, Rosen CJ, Shultz KL, Donahue LR, Turner CH, Sen S, Churchill GA, Muller R, and Beamer WG. 2004. Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. *J Bone Miner Res* 19:587-599.
98. Colbert LH, Rosen CJ, Goodpaster BH, Newman AB, Kritchevsky SB, Satterfield S, Kanaya AM, Taaffe DR, and Harris TB. 2004. Insulin-like growth factor-1. *J Am Geriatr Soc* 52:1962-1963.
99. Cranney A, Adachi JD, Rosen C, and Guyatt GH. 2004. Comment on Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. *Curr Med Res Opin* 20:1161-1162; author reply 1162-1163.
100. Fan X, Roy E, Zhu L, Murphy TC, Ackert-Bicknell C, Hart CM, Rosen C, Nanes MS, and Rubin J. 2004. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. *Endocrinology* 145:751-759.
101. Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, and Daifotis A. 2004. Weekly oral alendronic Acid in male osteoporosis. *Clin Drug Investig* 24:333-341.

102. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML and Horowitz M. 2004. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. *Bone* 35:1046-1058.
103. Rubin J, Chung LW, Fan X, Zhu L, Murphy TC, Nanes MS, and Rosen CJ. 2004. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. *Prostate* 58:41-49.
104. Stolzenberg-Solomon R, El-ghormli L, Schatzkin A, Rosen C, Clevidence B, Campbell W, Snyder K, Judd J, and Taylor P. 2004. Effects of a low fat, high fiber-carbohydrate diet on components of the IGF axis measured in plasma: a controlled feeding study in men. *Cancer Epidemiol Biomarkers Prev* 13:1086-1087.
105. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, and Rosen CJ. 2005. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med* 353:555-565.
106. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, and Beamer WG. 2005. Ovariectomy-induced bone loss varies among inbred strains of mice. *J Bone Miner Res* 20:1085-1092.
107. Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A, Hollis BW, Rosen CJ, Wysolmerski JJ, Dann P, Gundberg C, Stewart AF. 2005. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)<sub>2</sub> vitamin D. *J Bone Miner Res* 20:1792-1803.
108. Iida K, Rosen CJ, Ackert-Bicknell C, and Thorner MO. 2005. Genetic differences in the IGF-I gene among inbred strains of mice with different serum IGF-I levels. *J Endocrinol* 186:481-489.
109. Jassal SK, von Muhlen D, Barrett-Connor E, and Rosen CJ. 2005. Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study. *Osteoporos Int* 16:1948-1954.
110. Mohan S, Kapoor A, Singgih A, Zhang Z, Taylor T, Yu H, Chadwick RB, Chung YS, Donahue LR, Rosen C, Crawford GC, Wergedal J, Baylink DJ. 2005. Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. *J Bone Miner Res* 20:1597-1610.
111. Rosen CJ, Ackert-Bicknell C, Beamer WG, Nelson T, Adamo M, Cohen P, Bouxsein ML, and Horowitz MC. 2005. Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. *Pediatr Nephrol* 20:255-260.
112. Rosen CJ, Hochberg MC, Bonnicksen SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE. 2005. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. *J Bone Miner Res* 20:141-151.
113. Rubin MR, Schussheim DH, Kulak CA, Kurland ES, Rosen CJ, Bilezikian JP, and Shane E. 2005. Idiopathic osteoporosis in premenopausal women. *Osteoporos Int* 16:526-533.
114. Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, and Rosen CJ. 2005. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. *Gastroenterology* 129:464-475.
115. Sullivan SS, Rosen CJ, Halteman WA, Chen TC, and Holick MF. 2005. Adolescent girls in Maine are at risk for vitamin D insufficiency. *J Am Diet Assoc* 105:971-974.
116. Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, and Khosla S. 2005. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. *J Bone Miner Res* 20:1992-2001.
117. Welch JM, and Rosen CJ. 2005. Older women track and field athletes have enhanced calcaneal stiffness. *Osteoporos Int* 16:871-878.
118. Adamo ML, Ma X, Ackert-Bicknell CL, Donahue LR, Beamer WG, and Rosen CJ. 2006. Genetic increase in serum insulin-like growth factor-I (IGF-I) in C3H/HeJ compared with C57BL/6J mice is associated with increased transcription from the IGF-I exon 2 promoter. *Endocrinology* 147:2944-2955.

119. Akeson EC, Donahue LR, Beamer WG, Shultz KL, Ackert-Bicknell C, Rosen CJ, Corrigan J, and Davisson MT. 2006. Chromosomal inversion discovered in C3H/HeJ mice. *Genomics* 87:311-313.
120. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, and Black DM. 2006. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 91:1370-1375.
121. Boonen S, Marin F, Mellstrom D, Xie L, Desai D, Krege JH, and Rosen CJ. 2006. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. *J Am Geriatr Soc* 54:782-789.
122. Delahunty KM, Shultz KL, Gronowicz GA, Koczon-Jaremko B, Adamo ML, Horton LG, Lorenzo J, Donahue LR, Ackert-Bicknell C, Kream BE, Rosen CJ. 2006. Congenic mice provide in vivo evidence for a genetic locus that modulates serum insulin-like growth factor-I and bone acquisition. *Endocrinology* 147:3915-3923.
123. Gallagher JC, Rosen CJ, Chen P, Misurski DA, and Marcus R. 2006. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. *Bone* 39:1268-1275.
124. Gordon CM, Binello E, LeBoff MS, Wohl ME, Rosen CJ, and Colton AA. 2006. Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. *Osteoporos Int* 17:783-790.
125. He J, Rosen CJ, Adams DJ, and Kream BE. 2006. Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. *Bone* 38:826-835.
126. Hsu YH, Niu T, Terwedow HA, Xu X, Feng Y, Li Z, Brain JD, Rosen CJ, Laird N, and Xu X. 2006. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. *Hum Genet* 118:568-577.
127. Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, Laird N, Brain JD, Cummings SR, Bouxsein ML, Rosen CJ, Xu X. 2006. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. *Am J Clin Nutr* 83:146-154.
128. Hurley MM, Okada Y, Xiao L, Tanaka Y, Ito M, Okimoto N, Nakamura T, Rosen CJ, Doetschman T, and Coffin JD. 2006. Impaired bone anabolic response to parathyroid hormone in Fgf2<sup>-/-</sup> and Fgf2<sup>+/-</sup> mice. *Biochem Biophys Res Commun* 341:989-994.
129. Ishimori N, Li R, Walsh KA, Korstanje R, Rollins JA, Petkov P, Pletcher MT, Wiltshire T, Donahue LR, Rosen CJ, Beamer WG, Churchill GA, Paigen B. 2006. Quantitative trait loci that determine BMD in C57BL/6J and 129S1/SvImJ inbred mice. *J Bone Miner Res* 21:105-112.
130. Jiang J, Lichtler AC, Gronowicz GA, Adams DJ, Clark SH, Rosen CJ, and Kream BE. 2006. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. *Bone* 39:494-504.
131. Loladze AV, Stull MA, Rowzee AM, Demarco J, Lantry JH 3rd, Rosen CJ, Leroith D, Wagner KU, Hennighausen L, and Wood TL. 2006. Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. *Endocrinology* 147:5412-5423.
132. Munzer T, Rosen CJ, Harman SM, Pabst KM, St Clair C, Sorkin JD, and Blackman MR. 2006. Effects of GH and/or sex steroids on circulating IGF-I and IGF-BPs in healthy, aged women and men. *Am J Physiol Endocrinol Metab* 290:E1006-1013.
133. Rosen CJ, and Bouxsein ML. 2006. Mechanisms of disease: is osteoporosis the obesity of bone? *Nat Clin Pract Rheumatol* 2:35-43.
134. Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzman G, He W, Santora AC. 2006. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. *Curr Med Res Opin* 22:1745-1755.
135. Rubin J, Fan X, Rahnert J, Sen B, Hsieh CL, Murphy TC, Nanes MS, Horton LG, Beamer WG, and Rosen CJ. 2006. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. *Prostate* 66:789-800.



136. Sheu YT, Zmuda JM, Cauley JA, Moffett SP, Rosen CJ, Ishwad C, and Ferrell RE. 2006. Nuclear receptor coactivator-3 alleles are associated with serum bioavailable testosterone, insulin-like growth factor-1, and vertebral bone mass in men. *J Clin Endocrinol Metab* 91:307-312.
137. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, and Silverman S. 2006. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. *Mayo Clin Proc* 81:1013-1022.
138. Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ. 2006. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. *J Endocrinol* 189:289-299.
139. Ackert-Bicknell CL, and Rosen CJ. 2007. A chromosomal inversion within a Quantitative Trait Locus has a major effect on adipogenesis and osteoblastogenesis. *Ann N Y Acad Sci* 1116:291-305.
140. Beamer WG, Shultz KL, Ackert-Bicknell CL, Horton LG, Delahunty KM, Coombs HF 3rd, Donahue LR, Canalis E, and Rosen CJ. 2007. Genetic dissection of mouse distal chromosome 1 reveals three linked BMD QTLs with sex-dependent regulation of bone phenotypes. *J Bone Miner Res* 22:1187-1196.
141. Hsu YH, Xu X, Terwedow HA, Niu T, Hong X, Wu D, Wang L, Brain JD, Bouxsein ML, Cummings SR, Rosen CJ, Xu X. 2007. Large-scale genome-wide linkage analysis for loci linked to BMD at different skeletal sites in extreme selected sibships. *J Bone Miner Res* 22:184-194.
142. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, and Rosen CJ. 2007. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. *Endocrinology* 148:903-911.
143. Rubin CT, Capilla E, Luu YK, Busa B, Crawford H, Nolan DJ, Mittal V, Rosen CJ, Pessin JE, and Judex S. 2007. Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals. *Proc Natl Acad Sci U S A* 104:17879-17884.
144. Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, and Rosen CJ. 2007. Heterogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. *Osteoporos Int* 18:973-979.
145. Sibonga JD, Iwaniec UT, Shogren KL, Rosen CJ, and Turner RT. 2007. Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse. *Bone* 40:1013-1020.
146. Syed FA, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, and Khosla S. 2007. Effects of loss of classical estrogen response element signaling on bone in male mice. *Endocrinology* 148:1902-1910.
147. Tanner SJ, Hefferan TE, Rosen CJ, and Conover CA. 2007. Impact of Pregnancy-Associated Plasma Protein-A Deletion on the Adult Murine Skeleton. *J Bone Miner Res*. 23:655-662.
148. Yan J, Jiao Y, Li X, Jiao F, Beamer WG, Rosen CJ, and Gu W. 2007. Evaluation of gene expression profiling in a mouse model of L-gulonolactone oxidase gene deficiency. *Genet Mol Biol* 30:322-329.
149. Zalloua PA, Hsu YH, Terwedow H, Zang T, Wu D, Tang G, Li Z, Hong X, Azar ST, Wang B, Rosen CJ, Xu X. 2007. Impact of seafood and fruit consumption on bone mineral density. *Maturitas* 56:1-11.
150. Ackert-Bicknell CL, Demissie S, Marin de Evsikova C, Hsu YH, DeMambro VE, Karasik D, Cupples LA, Ordovas JM, Tucker KL, Cho K, Canalis E, Bapgen B, Churchill GA, Forejt J, Beamer W, Ferrari S, Bouxsein ML, Kiel DP, Rosen CJ. 2008. PPARG by dietary fat interaction influences bone mass in mice and humans. *J Bone Miner Res* 23:1398-1408. PMC2683155
151. Ackert-Bicknell, CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. 2008. Strain specific effects of Rosiglitazone on bone mass, body composition and serum IGF-I. *Endocrinology*. 150:1330-1340. PMC2654751
152. Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, and Rosen CJ. 2008. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. *J Clin Endocrinol Metab* 93:2166-2172. PMC2435646

153. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, and Rosen CJ. 2008. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. *Endocrinology* 149:2051-2061. PMC2329262
154. Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Rosen CJ, Lanza E, and Schatzkin A. 2008. The effects of a high-fruit and -vegetable, high-fiber, low-fat dietary intervention on serum concentrations of insulin, glucose, IGF-I and IGFBP-3. *Eur J Clin Nutr* 62:186-196.
155. Flood A, Mai V, Pfeiffer R, Kahle L, Rosen CJ, Lanza E, and Schatzkin A. 2008. Serum concentrations of insulin-like growth factor and insulin-like growth factor binding protein 3 and recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 17:1493-1498. PMC2597396
156. Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan SL, Rosen C, and Black D. 2008. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. *J Bone Miner Res* 23:1442-1448.
157. Godfrey JR, and Rosen CJ. 2008. Toward Optimal Health: Advances in Diagnosis and Preventive Strategies To Promote Bone Health in Women. *J Womens Health (Larchmt)* 9:1425-30.
158. Ishimori N, Stylianou IM, Korstanje R, Marion MA, Li R, Donahue LR, Rosen CJ, Beamer WG, Paigen B, and Churchill GA. 2008. Quantitative trait loci for BMD in an SM/J by NZB/BINJ intercross population and identification of Trps1 as a probable candidate gene. *J Bone Miner Res* 23:1529-1537. PMC2586053
159. Iwaniec UT, Trevisiol CH, Maddalozzo GF, Rosen CJ, and Turner RT. 2008. Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse. *Bone* 42:695-701.
160. Luu Y, Capilla E, Rosen C, Gilsanz V, Pessin J, Judex S, and Rubin CT. 2009. Mechanical Stimulation of Mesenchymal Stem Cell Proliferation and Differentiation Promotes Osteogenesis While Preventing Dietary Induced Obesity. *J Bone Miner Res* 24(1):50-61. PMC2689082
161. Maddalozzo GF, Iwaniec UT, Turner RT, Rosen CJ, and Widrick JJ. 2008. Whole-body vibration slows the acquisition of fat in mature female rats. *Int J Obes (Lond)* 32:1348-1354. PMC2586051
162. Shockley KR, Lazerenko OP, Czernik PJ, Rosen CJ, Churchill GA, and Lecka-Czernik B. 2009. Pparg nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. *J Cell Biochem* 106(2):232-46. PMC2631627
163. Simonelli C, Adler RA, Blake GM, Caudill JP, Khan A, Leib E, Maricic M, Prior JC, Eis SR, Rosen C, Kendler DL. 2008. Dual-Energy X-Ray Absorptiometry Technical issues: the 2007 ISCD Official Positions. *J Clin Densitom* 11:109-122.
164. Tanner SJ, Hefferan TE, Rosen CJ, and Conover CA. 2008. Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton. *J Bone Miner Res* 23:655-662. PMC2674540
165. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, and Leroith D. 2009. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. *Faseb J* 23:709-19. PMC2653987
166. Fritton JC, Emerton KB, Sun H, Kawashima Y, Mejia W, Wu Y, Rosen CJ, Panus D, Bouxsein M, Majeska RJ, Schaffler MB, and Yakar S. 2009. Growth Hormone Protects Against Ovariectomy-Induced Bone Loss in States of Low Circulating IGF-1 \*. *J Bone Miner Res* [Epub ahead of print]. PMC2836075
167. Yuan R, Tsaih SW, Petkova SB, de Evsikova CM, Xing S, Marion MA, Bogue MA, Mills KD, Peters LL, Bult CJ, Rosen CJ, Sundberg JP, Harrison DE, Churchill GA, and Paigen B. 2009. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. *Aging Cell* 1;8(3):277-287. PMC2768517
168. Mödder UI, Monroe DG, Fraser DG, Spelsberg TC, Rosen CJ, Géhin M, Chambon P, O'Malley BW, and Khosla S. 2009. Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. *J Biol Chem* 284(28):18767-77. PMC2707192

169. Bredella MA, Fazeli PK, Miller KK, Misra M, Torriani M, Thomas BJ, Ghomi RH, Rosen CJ, and Klibanski A. 2009. Increased bone marrow fat in anorexia nervosa. *J Clin Endocrinol Metab* 94(6):2129-36. PMC2690416
170. Ecklund K, Vajapeyam S, Feldman HA, Buzney CD, Mulkern RV, Kleinman PK, Rosen CJ, Gordon CM. Bone marrow changes in adolescent girls with anorexia nervosa. *J Bone Miner Res*. 2010 Feb;25(2):298-304
171. Fritton JC, Kawashima Y, Mejia W, Courtland HW, Elis S, Sun H, Wu Y, Rosen CJ, Clemmons D, and Yakar, S. 2010. The insulin-like growth factor-1 (IGF-1) binding protein acid-labile subunit (ALS) alters mesenchymal stromal cell fate. *J Biol Chem* 285(7):4709-14.
172. Zaidi M, Turner CH, Canalis E, Pacifici R, Sun L, Iqbal J, Guo XE, Silverman S, Epstein S, and Rosen CJ. 2009. Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. *Curr Osteoporos Rep* 7:118-126.
173. Turner RT, Rosen CJ, and Iwaniec UT. 2010. Effects of alcohol on skeletal response to growth hormone in hypophysectomized rats. *Bone*. 46:806-812
174. Fazeli PK, Bredella MA, Misra M, Meenaghan E, Rosen CJ, Clemmons DR, Breggia A, Miller KK, and Klibanski A. 2010. Preadipocyte Factor-1 Is Associated with Marrow Adiposity and Bone Mineral Density in Women with Anorexia Nervosa. *J Clin Endocrinol Metab* 95(1):407-13. PMC2805488
175. Menagh P, Turner R, Jump D, Wong C, Lowry M, Yakar S, Rosen C, and Iwaniec UT. 2009. Growth Hormone Regulates the Balance Between Bone Formation and Bone Marrow Adiposity. *J Bone Miner Res*. 25:757-768
176. Demambro V, Kawai M, Clemens T, Fulzele K, Maynard J, Marin de Evsikova C, Johnson K, Canalis E, Beamer W, Rosen C, et al. 2010. A Novel Spontaneous Mutation of Irs1 in Mice Results in Hyperinsulinemia, with Reduced Growth, Bone Mass, and Adipogenesis. *J Endocrinol* 204(3):241-53. NIHMS182321
177. Elis S, Courtland HW, Wu Y, Rosen CJ, Sun H, Jepsen KJ, Majeska RJ, and Yakar S. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties, even in the absence of tissue IGF-1. *J Bone Miner Res*. 2010;25 (6):1257-66.
178. Elis S, Courtland HW, Wu Y, Rosen CJ and Yarkar S. 2010. Elevated serum IGF-I levels synergize PTH action on the skeleton only when the tissue IGF-I axis is intact. *J Bone Min Res* 2010 Sep;25(9):2051-8.
179. Fretz JA, Nelson T, Xi Y, Adams DJ, Rosen CJ, and Horowitz MC. 2010. Altered Metabolism and Lipodystrophy in the Early B-Cell Factor 1-Deficient Mouse. *Endocrinology*. 151; 1611-22.
180. Bredella MA Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK. 2010. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-I in obese women. *Obesity* 2011, 19: 49-53.
181. Kerver JM, Gardiner JC, Dorgan JF, Rosen CJ, and Velie EM. Dietary predictors of the insulin-like growth factor system in adolescent females: results from the Dietary Intervention Study in Children (DISC). *Am J Clin Nutr* 91:643-650. PMC2824156
182. Russell M, Mendes N, Miller KK, Rosen CJ, Lee H, Klibanski A, and Misra M. Visceral fat is a negative predictor of bone density measures in obese adolescent girls. *J Clin Endocrinol Metab* 2010; 95:1247-1255. .
183. Kawai M, Delany AM, Green CB, Adamo ML, and Rosen CJ. 2010 Nocturnin suppresses Igf1 expression in bone by targeting the 3'UTR of IGF1 mRNA. *Endocrinology* 2010 Oct;151(10):4861-70.
184. Beamer WG, Shultz KL, Coombs HF, Demambro VE, Reinholdt LG, Ackert-Bicknell CL, Canlis E, Rosen CJ, Donahue LR. 2011 BMD regulation on mouse Chr 1 candidate genes and response to ovariectomy or dietary fat. *J Bone Miner Res*. 2011 Jan;26(1):88-99.
185. Kawai M, Green CB, Lecka Czernik B, Douris N, Gilbert MR, Kokima S, Ackert-Bicknell C, Garg N, Horowitz MC, Adamo ML, Clemmons DR, Rosen CJ. A circadian regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-g nuclear translocation *Proc Natl Acad Sci USA* 2010 23: 10508-1013.

186. Devlin M, Cloutier A, Thomas N, Panus D, Lotinun S, Pinz I, Baron R, Rosen CJ, Boussein ML. 2010 Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. *J Bone Miner Res* 25:2078-2088.
187. Urs S, Venkatesh D, Tang Y, Henderson T, Yang X, Friesel RE, Rosen CJ and Liaw L. 2010 Sprouty 1 is a critical regulatory switch of mesenchymal stem cell lineage allocation. *FASEB J* 24:3264-3273.
188. Courtland HW, DeMambro V, Maynard J, Sun H, Elis S. Rosen CJ and Yakar S. 2010. Sex specific regulation of body size and bone slenderness by the acid-labile subunit. *J Bone Min Res* 25:2059-2068.
189. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Harrington LM, Breggia A, Rosen CJ and Miller KK. Determinants of bone density in obese premenopausal women. *Bone* 2010; 8(4):748-54
190. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. 2011 Report on dietary reference intakes for calcium and vitamin D. *J Clin Endocrinol Metab* 2011 96: 53-58.
191. Kawai, M Breggia AC, DeMambro VE, Canalis E, Boussein ML, Beamer WG, Clemmons DR and Rosen CJ The heparin-binding domain of IGFBP-2 has IGF binding-independent biologic activity in the growing skeleton *J Biol Chem* 2011,14670-80.
192. Cohen A, Recker RR, Lappe J, Dempster DW, Cremers S, McMahon DJ, Stein EM, Fleischer J, Rosen CJ, Rogers H, Staron RB, Lemaster J, Shane E. Premenopausal women with idiopathic low trauma fractures and or low bone mineral density. *Osteoporosis Int* 2012 12:171-82.
193. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Rosen CJ and Delafontaine P. Low circulating IGF-I increases atherosclerosis in ApoE deficient mice. *Am J Physiol Heart Circ Physiol* 2011. May;300(5):H1898-906
194. Maile LA, Demambro VE, Wai C, Aday AW, Capps BE, Beamer WG, Rosen CJ, Clemmons DR. An essential role for the association of CD47 to SHPS-1 in skeletal remodeling *J Bone Min Res* 2011 26: 2068-81
195. dePaula FJ, de Paula I, Bornstein S, Rostama B, le, P, Lotinun S, Baron R, Rosen CJ. VDR haploinsufficiency impacts body composition and skeletal acquisition in a gender specific manner. *Calcif Tissue Int* 2011;89:79-91
196. Elis S, Wu Y, Courtland HW, Cannata D, Sun H, Beth-On M, Liu C, Jasper H, Domene H, Karabas L, Guida C, Basta-Pijakic J, Cardos L, Rosen CJ, Frystyk J, Yakar S. Unbound IGF-I enhances somatic growth. *Dis Model Mech* 2011;5: 649-58.
197. Courtland HW, Elis S, Wu Y, Sun H, Rosen CJ, Jepsen KJ and Yakar S. Serum IGF-I affects skeletal acquisition in a temporal and compartment specific manner. *Plos One* 2011 Mar 18;6(3):e14762
198. Elis S, Wu Y, Courtland HW, Sun H, Rosen CJ, Adamo ML and Yakar S. Increased serum IGF-I levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue IGF-I gene expression. *Aging Cell* 2011 10: 547-50.
199. Motyl, K de Paula, ID Maloney A, Bornstein, S, dePaula, F Lotinun S, Baron R, Houseknecht KL, Rosen CJ. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain, *Bone* 2012: 50: 490-8.
200. Guntur AR and Rosen CJ. New insights into osteoblasts and their role in bone formation: The central role of PI3Kinase. *J Endocrinol* 2011;211: 123-130.
201. Shafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ et al Change in Undercarboxylated Osteocalcin is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study) *J Clin Endocrinol Metab* 96: 1982-89
- 202.** Guntur A, Kawai M, Le P, Boussein ML, Bornstein S, Green CG and Rosen CJ. An essential role for the circadian-regulated gene Nocturnin in Osteogenesis: The Importance of local timekeeping in skeletal homeostasis. *Ann NY Acad Sci* 2011 1237: 58-63.

203. Aronis KN, Kilim H, Chamberland JP, Breggia A, Rosen CJ, Mantzoros CS. Preadipocyte Factor-1 Levels Are Higher in Women with Hypothalamic Amenorrhea and Are Associated with Bone Mineral Content and Bone Mineral Density through a Mechanism Independent of Leptin. *J Clin Endocrinol Metab.* 2011 Jul 27.
204. Cohen A, Dempster DW, Recker RR, Stein EM, Lappe JM, Zhou H, Wirth AJ, van Lenthe GH, Kohler T, Zwahlen A, Müller R, Rosen CJ, Cremers S, Nickolas TL, McMahon DJ, Rogers H, Staron RB, Lemaster J, Shane E. Abnormal Bone Microarchitecture and Evidence of Osteoblast Dysfunction in Premenopausal Women with Idiopathic Osteoporosis. *J Clin Endocrinol Metab.* 2011; 96: 3095-3110
205. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. *J Am Diet Assoc.* 2011 Apr;111(4):524-7.
206. Le P, Kawai M, Bornstein S, Demambro VE, Horowitz MC, Rosen CJ. A high-fat diet induces bone loss in mice lacking the *alox5* gene. *Endocrinology.* 2012 Jan;153(1):6-16.
207. Urs S, Henderson T, Le P, Rosen CJ, Liaw L. Tissue-specific expression of *Sprouty1* in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction. *Br J Nutr.* 2011 Dec 6:1-9.
208. Demambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ, Clemmons D. IGFBP-2 is required for osteoclast differentiation. *J Bone Miner Res* 2012;27:390-400
209. Bragdon B, Bonor J, Schultz KL, Beamer WG, Rosen CJ, Nohe A. BMP receptor1a localization causes increased BMP2 signaling in mice exhibiting increased peak bone mass phenotype. *J Cell Physiol* 2011: 2870-9.
210. Bragdon B, D'Angelo A, Gurski L, bonor J, Schultz KL, Beamer WG, Rosen CJ, Nohe A. Altered plasma membrane dynamics of BMP receptor type in a low bone mass mouse model. *Bone* 2012 50: 189-99.
211. Beamer WG, Shultz KL, Coombs HF, Horton LG, Donahue LR and Rosen CJ. Multiple quantitative trait loci for cortical and trabecular bone regulation map to mid-distal mouse chromosome 4 that shares linkage homology to human ch 1p36. *J Bone Miner Res* 2012 Jan;27(1):47-57
212. Guntur AR, Rosen CJ and Naski MC. N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. *Bone* 2012 50: 54-62.
213. Zhang Q, Wastney ME, Rosen CJ, Beamer WG, Weaver CM. IGF-I increases bone calcium accumulation only during rapid growth in female rats. *J Nutr* 2011 141: 2010-2016.
214. Seger RL, Cross RA, Rosen CJ, Causey RC, Gundberg CM, Carpenter TO, Chen TC, Halteman WA, Holick MF, Jakubas WJ, Keisler DH, Seger RM and Servello FA. Investigating the mechanism for maintaining eucalcemia despite immobility and anuria in the hibernating American black bear. *Bone* 2011;49: 1205-1212.
215. Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ, Hemphill LC, Wu Z, Rifai N, Utz AL, Miller K. Effects of growth hormone in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. *Eur J Endocrinol.* 2012 166(4):601-11.
216. Bredella MA, Fazeli PK, Freedman LM, Calder G, Lee H, Rosen CJ, Klibanski A. Young Women with Cold-Activated Brown Adipose Tissue Have Higher Bone Mineral Density and Lower Pref-1 than Women without Brown Adipose Tissue: A Study in Women with Anorexia Nervosa, Women Recovered from Anorexia Nervosa, and Normal-Weight Women. *J Clin Endocrinol Metab.* 2012; Apr 97(4):E584-90.
217. Divasta AD, Feldman HA, Giancaterino C, Rosen CJ, Leboff MS, Gordon CM. The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. *Metabolism.* 2012 Jul;61(7):1010-20

218. Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, Crane J, Frassica F, Zhang L, Rodriguez JP, Jia X, Yakar S, Xuan S, Efstratiadis A, Wan M, Cao X. Matrix IGF-I maintains bone mass by activation of mTOR in mesenchymal stem cells. *Nat Med*. 2012 Jul;18(7):1095-101
219. Fazeli PK, Bredella MA, Freedman L, Thomas BJ, Breggia A, Meenaghan E, Rosen CJ, Klibanski A. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. *J Bone Miner Res*. 2012; 27:1864-71
220. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulin-Like Growth Factor (IGF) Binding Protein 2 Functions Coordinately with Receptor Protein Tyrosine Phosphatase  $\beta$  and the IGF-I Receptor To Regulate IGF-I-Stimulated Signaling. *Mol Cell Biol*. 2012 Oct;32(20):4116-30.
221. Schwartz AV, Sigurdsson S, Hue TF, Lang T, Harris TG, Rosen CJ et al Vertebral bone marrow fat is associated with lower trabecular BMD and prevalent vertebral fractures in older adults. *J Clin Endocrinol Metab* 2013, 98: 2294-2300.
222. Faje A, Katzman D, Breggia A, Fazeli P, Estella N, Rosen CJ. Inhibition of Pref-1 (Preadipocyte Factor 1) by Estradiol in Adolescent Girls with Anorexia Nervosa is Associated with Improvement in Lumbar Bone Mineral Density. *Clinical Endocrinology* 2013: 326-332.
223. Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ, Hemphill LC, Wu Z, Rifai N, Utz AL, Miller KK. Effects of GH in women with abdominal adiposity: a 6 month randomized double blind placebo controlled trial. *Eur J Endocrinol*. 2012 Apr;166(4):601-11.
224. Faje AT, Fazeli P, Katzman DK, Miller KK, Breggia A, Rosen CJ, Mendes N, Klibanski A, Misra M. Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. *Bone*. 2012 Sep;51(3):474-9.
225. Bredella MA, Klibanski A, Rosen CJ. IGFBP-2 is a negative predictor of cold induced brown fat and bone mineral density in young non-obese women. *Bone* 2013 56: 336-339.
226. Pino AM, Rosen CJ and Rodriguez JP. In osteoporosis, differentiation of MSCs improves bone marrow adipogenesis. *Biol Res* 2012; 45:279-287.
227. Du B, Cawthorn WP, Su A, Doucette CR, Yao Y, Hemati N, Ampert S, MocCoin C, Broome DT, Rosen CJ, Yang G, MacDougald OA. The transcription factor Prrx1 inhibits adipogenesis by activating TGF $\beta$  signaling. *JBC* 2012 epub
228. Flynn JM, Spusta SC, Rosen CJ, Melov S. Single cell gene expression profiling of cortical osteoblast lineage cells. *Bone* 2013 53: 174-181.
229. Smith SS, Kessler CB, Shenoy V, Rosen CJ and Delany AM. Igf1 3' untranslated region: strain specific polymorphisms and motifs regulating IGF-I in osteoblasts. *Endocrinology*; 2013; 154:253-262.
230. Collins JN, Kirby BJ, Woodrow JP, Gagel RF, Rosen CJ, Sims NA, and Kovacs, CS. Lactating Ctggrp nulls lose twice normal bone mineral content due to fewer osteoblasts and more osteoclasts, while bone mass is fully restored post-weaning in association with upregulation of Wnt signaling and other novel genes. *Endocrinology* 2013 Apr; 154(4):1400-13
231. Motyl KJ, Bishop KA, Demambro VE, Bornstein SA, Le P, Kawai M, Lotinun S, Horowitz MC, Baron R, Bouxsein ML, Rosen CJ. Altered thermogenesis and impaired bone remodeling in Misty mice. *J Bone Miner Res*. 2013. Sep;28(9):1885-97. doi: 10.1002/jbmr.1943 PMID 23553822
232. Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, Vittinghoff E, Siggeirsdottir K, Sigurdsson G, Oskarsdottir D, Shet K, Palermo L, Gudnason V, Li X. Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. *J Clin Endocrinol Metab* 2013 98: 2294-2300.
233. Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, Müller R, Zhao B, Guo X, Lang T, Saeed I, Liu XS, Guo XE, Cremers S, Rosen CJ, Stein EM, Nickolas TL, McMahon DJ, Young P, Shane E. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. *J Clin Endocrinol Metab* 2013 Jun;98(6):2562-72.

234. Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, Lecka-Czernik B. Inducible brown adipose tissue or beige fat is anabolic for the skeleton. *Endocrinology* 2013 Aug;154(8):2687-701. doi: 10.1210/en.2012-2162. Epub 2013 May 21 PMID 23696565
235. Nallamshetty S, Wang H, Rhee EJ, Kiefer FW, Brown JD, Lotinun S, Le P, Baron R, Rosen CJ, Plutzky J. Deficiency of Retinaldehyde Dehydrogenase 1 Induces BMP2 and Increases Bone Mass In Vivo. *PLoS One*. 2013 Aug 9;8(8):e71307.
236. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, Kapahi P, Nelson MD, Kennedy BK, Melov S. . Late-life rapamycin treatment reverses age-related heart dysfunction. *Aging Cell*. 2013: Oct;12(5):851-62.
237. Xi G, Solum MA, Wai C, Maile LA, Rosen CJ, Clemmons DR. The Heparin-Binding Domains of IGFBP-2 Mediate Its Inhibitory Effect on Preadipocyte Differentiation and Fat Development in Male Mice. *Endocrinology*. 2013;154: 4146-4157
238. Zhang V, Jiang X, Farukhi YZ, Rosen CJ, Schnatz PF. Vitamin D and Calcium: What Do We Need to Know? *Clin Obstet Gynecol*. 2013; 2013 Dec;56(4):654-8.
239. Youm YH, Grant RW, McCabe LR, Albarado DC, Nguyen KY, Ravussin A, Pistell P, Newman S, Carter R, Laque A, Münzberg H, Rosen CJ, Ingram DK, Salbaum JM, Dixit VD. Canonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging. *Cell Metab*. 2013 Oct 1;18(4):519-532.
240. Doucette CR and Rosen CJ. Bone-fat interactions: The Cold Facts About Marrow Adiposity. *Osteoporos Int* 2013 24 Suppl 3 S443-478.
241. Du B, Cawthorn WP, Su A, Doucette CR, Yao Y, Hemati N, Kampert S, McCain C, Broome DT, Rosen CJ, Yang G, Macdougald OA. The transcription factor paired-related homeobox 1 (Prrx1) inhibits adipogenesis by activating TGF $\beta$  signaling. *J Biol Chem*. 2013 288(5):3036-3047 PMID: PMC3561528
242. Bredella MA, Klibanski A, Rosen CJ. IGFBP-2 is a negative predictor of cold induced brown fat and bone mineral density in young non-obese women. *Bone* 2013 53: 336-339 PMID: PMC23291564
243. Guntur AR, Le PT, Farber CR and Rosen CJ. Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. *Endocrinology* 2014;Jan 17. PMID: PMC24437492
244. Bredella MA, Gerweck AV, Barber LA, Breggia A, Rosen CJ, Torriani M, Miller KK. Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women. *Bone*. 2014 May;62:29-35
245. Scheller E and Rosen CJ. What's a matter with MAT? Marrow adipose tissue, metabolism and skeletal health. *Ann NY Acad Sci*. 2014 Epub
246. Scheller EL, Troiano N, Vanhoutan JN, Bouxsein MA, Fretz JA, Xi Y, Nelson T, Katz G, Berry R, Church CD, Doucette CR, Rodeheffer MS, Macdougald OA, Rosen CJ, Horowitz MC. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. *Methods in Enzymology* 2014;537:123-39.
247. Yagi M, Arentsen L, Shanley RM, Rosen CJ, Kidder LS, Sharkey LC, Yee D, Koizumi M, Ogawa K, Hui SK. A Dual-Radioisotope Hybrid Whole-Body Micro-Positron Emission Tomography/Computed Tomography System Reveals Functional Heterogeneity and Early Local and Systemic Changes Following Targeted Radiation to the Murine Caudal Skeleton. *Calcif Tissue Int*. 2014 Feb 23. [Epub ahead of print
248. Bredella MA, Gill CM, Rosen CJ, Klibanski A, Torriani M. Positive effects of brown adipose tissue on femoral bone structure. *Bone*. 2014 Jan;58:55-8. PMID: PMC3855336 (available 1/1/15)

249. Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell B, Broome DT, Soliman SS, DelProposto JL, Lumeng CN, Mitra A, Pandit SV, Gallagher KA, Miller JD, Krishnan V, Hui SK, Bredella MA, Fazeli PK, Klibanski A, Horowitz MC, Rosen CJ, MacDougald OA. Bone Marrow Adipose Tissue Is an Endocrine Organ that Contributes to Increased Circulating Adiponectin during Caloric Restriction. *Cell Metabolism* 2014 S1550-4131(14) Aug 5;20(2):368-75
250. Bonnet N, Somm E, Rosen CJ. Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids. *Bone*. 2014 Aug 1;68C:100-107. doi: 10.1016/j.bone.2014.07.024.
251. Pittas AG, Dawson-Hughes B, Sheehan PR, Rosen CJ, Ware JH, Knowler WC, Staten MA; D2d Research Group Rationale and design of the vitamin d and type 2 diabetes (d2d) study: a diabetes prevention trial. *Diabetes Care*. 2014 Dec;37(12):3227-34
252. Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. *Bone*. 2015 Feb 26;75:161-169
253. Doucette CR, Horowitz MC, Berry R, MacDougald OA, Anunciado-Koza R, Koza RA, **Rosen CJ**.  
A High Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter Trabecular or Cortical Bone Mass in C57BL/6J Mice. *J Cell Physiol*. 2015 Feb 7.
254. Doucette CR and Rosen CJ. Inducible Mouse models of bone loss. *Curr Protocols in Mouse Biology*. Dec 2014
255. Motyl KL, DeMambro VE, Barlow Olshan D Nagano K, Baron R, Rosen CJ, Houseknecht KL. Propranolol attenuates risperidone-induced trabecular bone loss in female mice, *Endocrinology*2015: Jul;156(7):2374-83
256. Garfinkel BP, Arad S, Le PT, Bustin M, Rosen CJ, Gabet Y, Orly J. Proportionate Dwarfism in Mice Lacking Heterochromatin Protein 1 Binding Protein 3 (HP1BP3) is associated with alterations in the endocrine IGF-1 pathway. *Endocrinology*. 2015: 156: 4558-70.
257. Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nat Commun*. 2015 Aug 6:6708
258. Stohn JP, Wang Q, Siviski ME, Kennedy K, Jin YR, Kacer D, DeMambro V, Liaw L, Vary CP, Rosen CJ, Prudovsky I, Lindner V. *Cthrc1* controls adipose tissue formation, body composition, and physical activity. *Obesity (Silver Spring)*. 2015 Aug;23(8):1633-42. doi: 10.1002/oby.21144. Epub 2015 Jul 7
259. Klein GL, Herndon DN, Le PT, Andersen CR, Benjamin D, Rosen CJ. The effect of burn on serum concentrations of sclerostin and FGF23. *Burns*. 2015 Apr 24. pii: S0305-4179
260. Sharma A, Flom PL, Rosen CJ, Schoenbaum EE. Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women. *Bone*. 2015 Aug;77:24-30.
261. Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa. Fazeli PK, Faje AT, Cross EJ, Lee H, Rosen CJ, Bouxsein ML, Klibanski A. *Bone*. 2015 Aug;77:6-11
262. Xi G, Rosen CJ, Clemmons DR. IGF-I and IGFBP-2 stimulate AMPK activation and autophagy which are required for osteoblast differentiation. *Endocrinology* 2016, 157: 268-281
263. Turner RT, Dube M, Branscum AJ, Wong CP, Olson DA, Zhong X, Kweh MF, Larkin IV, Wronski TJ, Rosen CJ, Kalra SP, Iwaniec UT. Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss. *J Endocrinol* 2015 Dec. 227: 129-141.
264. Liu Z, Kennedy OD, Cardoso L, Basta-Pijakic J, Partridge NC, Schaffler MB, Rosen CJ, Yakar S. DMP-1 mediated Ghr gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH, *FASEBJ*, Feb 2016 30:: 635-652.
265. Xi G, Shen X, Rosen CJ, Clemmons DR. IRS-1 functions as a molecular scaffold to coordinate IGF-I/IGFBP-2 signaling during osteoblast differentiation. *J Bone Miner Res*. 2016 Jan 16. doi: 10.1002/jbmr.2791. [Epub ahead of print



266. Liaw L, Prudovsky I, Koza RA, Anunciado-Koza RV, Siviski ME, Lindner V, Friesel RE, **Rosen CJ**, Baker PR, Simons B, Vary CP. Lipid Profiling of In Vitro Cell Models of Adipogenic Differentiation J Cell Biochem. 2016 Feb 22. doi: 10.1002/jcb.25522. [Epub ahead of print]
267. Ackert-Bicknell CL and **Rosen CJ**. Passenger Gene Mutations: Unwanted Guests in Genetically Modified Mice. J Bone Min Res 2016 31: 270-273.
268. Fan, Y., Hanai, J., Le, P.T., Ruiye, B., Maridas, D., Figueroa, C.A., Kir, S., Zhou, X., Mannstadt, M., Baron, R., Bronson, R.T., Horowitz, M.C., Wu, J., Bilezikian, J.P., Dempster, D.D., **Rosen, C.J.**, Lanske, B., The Critical Role of Parathyroid Hormone in Mesenchymal Cell Fate and Bone Marrow Adipogenesis. Cell Metabolism, 2017 In Press
269. Liu JM, **Rosen CJ**, Ducy P, Kousteni S, Karsenty G. Regulation of Glucose Handling by the Skeleton. Diabetes 2016 Nov;65(11):3225-3232
270. Calabrese GM, Mesner LD, Stains JP, Tommasini SM, Horowitz MC, **Rosen CJ**, Farber CR. Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. Cell Syst. 2016 Nov 15. pii: S2405-4712(16)30333-7
271. Pino AM, Miranda M, Figueroa C, Rodríguez JP, **Rosen CJ**. Qualitative Aspects of Bone Marrow Adiposity in Osteoporosis. Frontiers in Endocrinology 2016 October 7: 139
272. Stechschulte LA, Czernik PJ, Rotter ZC, Tausif FN, Corzo CA, Marciano DP, Asteian A, Zheng J, Bruning JB, Kamenecka TM, **Rosen CJ**, Griffin PR, Lecka-Czernik B. PPAR $\gamma$  Post-translational Modifications Regulate Bone Formation and Bone Resorption. EBioMedicine. 2016 Aug;10:174-84
273. Miranda M, Pino AM, Fuenzalida K, Rosen CJ, Seitz G, Rodríguez JP. Characterization of Fatty Acid Composition in Bone Marrow Fluid From Postmenopausal Women: Modification After Hip Fracture. J Cell Biochem. 2016 Oct;117(10):2370-6.
274. Calabrese G, Mesner LD, Foley PL, **Rosen CJ**, Farber CR. Network Analysis Implicates Alpha-Synuclein (Snca) in the Regulation of Ovariectomy-Induced Bone Loss. Sci Rep. 2016 Jul 5;6:29475
275. Devlin MJ, Brooks DJ, Conlon C, Vliet Mv, Louis L, **Rosen CJ**, Bouxsein ML. Daily leptin blunts marrow fat but does not impact bone mass in calorie-restricted mice. J Endocrinol. 2016 Jun;229(3):295-306
276. Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikian JP, Dempster DW, Rosen CJ, Lanske B. PTH directs bone marrow mesenchymal cell fate. Cell Metabolism 2017 an 25. pii: S1550-4131(17)30036-0.
277. Maridas DE, DeMambro VE, Le PT, Nagano K, Baron R, Mohan S, **Rosen CJ**. IGFBP-4 regulates adult skeletal growth in a sex-specific manner. J Endocrinol. 2017 Apr;233(1):131-144. doi: 10.1530/JOE-16-0673. Epub 2017 Feb 9
278. Jin YR, Stohn JP, Wang Q, Nagano K, Baron R, Bouxsein ML, **Rosen CJ**, Adarichev VA, Lindner V. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1. Bone. 2017 Apr;97:153-167. doi: 10.1016/j.bone.2017.01.022. Epub 2017 Jan 21
279. Calabrese GM, Mesner LD, Stains JP, Tommasini SM, Horowitz MC, **Rosen CJ**, Farber CR. Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. Cell Syst. 2017 Jan 25;4(1):46-59.e4. doi: 10.1016/j.cels.2016.10.014. Epub 2016 Nov 17.
280. Pino AM, Miranda M, Figueroa C, Rodríguez JP, **Rosen CJ**. Qualitative Aspects of Bone Marrow Adiposity in Osteoporosis. Front Endocrinol (Lausanne). 2016 Oct 25;7:139. eCollection 2016 Oct 25
281. Liu P, Ji, Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, Abu-Amer W, Sudeh Izadmehr S, Zhou B, Shin AC, Latif R, Thangeswaran P, Gupta A, Li J, Shnyder V, Robinson ST, Yu YE, Zhang X, Yang F, Lu P, Zhou Y, Zhu LL, Oberlin DJ, Davies TF, Reagan MR, Brown A, T, Kumar A, Epstein S, Iqbal J, Avadhani NG, New MI, Molina H, van Klinken JB, Guo EX, Buettner C, Haider S, Bian Z, Sun L, **Rosen CJ** & Zaidi M Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature 2017 June 1

282. Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, **Rosen CJ**, Reagan MR. Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. *Endocrinology*. 2017 Oct 1;158(10):3369-3385.
283. Uchimura T, Hollander JM, Nakamura DS, Liu Z, **Rosen CJ**, Georgakoudi I, Zeng L. Development. 2017 Oct 1;144(19):3533-3546.
284. Maridas DE, DeMambro VE, Le PT, Mohan S, **Rosen CJ**. IGFBP4 Is Required for Adipogenesis and Influences the Distribution of Adipose Depots. *Endocrinology*. 2017 Oct 1;158(10):3488-3500. doi: 10.1210/en.2017-00248
285. Liu Z, Han T, Werner H, **Rosen CJ**, Schaffler MB, Yakar S. Reduced serum IGF-1 associated with hepatic osteodystrophy is a main determinant of low cortical but not trabecular bone mass. *J Bone Miner Res*. 2017 Sep 13
286. Li X, Shet K, Xu K, Rodríguez JP, Pino AM, Kurhanewicz J, Schwartz A, **Rosen CJ**. . Unsaturation level decreased in bone marrow fat of postmenopausal women with low bone density using high resolution magic angle spinning (HRMAS) <sup>1</sup>H NMR spectroscopy. *Bone*. 2017 Dec;105:87-92
287. Rendina-Ruedy E, Guntur AR, **Rosen CJ** Intracellular lipid droplets support osteoblast function. *Adipocyte*. 2017 Jul 3;6(3):250-258
288. Maridas DE, DeMambro VE, Le PT, Nagano K, Baron R, Mohan S, and Rosen CJ. IGFBP-4 regulates adult skeletal growth in a sex specific manner. *J Endocrinol* 2017 233: 131-144.
289. Guntur AR, Gerencser AA, T Le P, DeMambro VE, Bornstein SA, Mookerjee SA, Maridas DE, Clemmons DE, Brand MD, **Rosen CJ**. Osteoblast like MC3T3-E1 cells prefer glycolysis for ATP production but adipocyte like 3T3- L1 cells prefer oxidative phosphorylation. *J Bone Miner Res*. 2018 Jan 17. doi: 10.1002/j
290. Mistry SD, Woods GN, Sigurdsson S, Ewing SK, Hue TF, Eiriksdottir G, Xu K, Hilton JF, Kado DM, Gudnason V, Harris TB, **Rosen CJ**, Lang TF, Li X, Schwartz AV Sex hormones are negatively associated with vertebral bone marrow fat. *Bone*. 2017 Dec 11;108:20-24.
291. Fazeli PK, Faje A, Bredella MA, Polineni S, Russell S, Resulaj M, **Rosen CJ**, Klibanski A. Changes in marrow adipose tissue with short-term changes in weight in premenopausal women with anorexia nervosa. *Eur J Endocrinol*. 2018 Dec 1. pii: EJE-18-0824.R1. doi: 10.1530/EJE-18-0824. [Epub ahead of print]
292. Rokoff LB, Rifas-Shiman SL, Switkowski KM, Young JG, **Rosen CJ**, Oken E, Fleisch AF. Body composition and bone mineral density in childhood. *Bone*. 2018 Dec 15;121:9-15. doi: 10.1016/j.bone.2018.12.009. [Epub ahead of print]
293. Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, Zhou C, Chou J, Parkman VA, Novick SJ, Strutzenberg TS, Pascal BD, Le PT, Brooks DJ, Roche AM, Gerber KK, Mattheis L, Chen W, Tu H, Bouxein ML, Griffin PR, Baron R, **Rosen CJ**, Bonewald LF, Spiegelman BM. Irisin Mediates Effects on Bone and Fat via  $\alpha$ V Integrin Receptors. *Cell*. 2018 Dec 13;175(7):1756-1768.e17. doi: 10.1016/j.cell.2018.10.025.

294. Su S, Guntur AR, Nguyen DC, Fakory SS, Doucette CC, Leech C, Lotana H, Kelley M, Kohli J, Martino J, Sims-Lucas S, Liaw L, Vary C, **Rosen CJ**, Brown AC. A Renewable Source of Human Beige Adipocytes for Development of Therapies to Treat Metabolic Syndrome. *Cell Rep*. 2018 Dec 11;25(11):3215-3228.e9. doi: 10.1016/j.celrep.2018.11.037
295. Maridas DE, Rendina-Ruedy E, Helderman RC, DeMambro VE, Brooks D, Guntur AR, Lanske B, Bouxsein ML, **Rosen CJ**. . Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton. *FASEB J*. 2018 Oct 24.
296. Liu Z, Solesio ME, Schaffler MB, Frikha-Benayed D, **Rosen CJ**, Werner H, Kopchick JJ, Pavlov EV, Abramov AY, Yakar S. Mitochondrial Function Is Compromised in Cortical Bone Osteocytes of Long-Lived Growth Hormone Receptor Null Mice. *J Bone Miner Res*. 2019 Jan;34(1):106-122. doi: 10.1002/jbmr.3573. Epub 2018 Sep 14.
297. Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ, Atkinson EJ, Joyner MJ, **Rosen CJ**, Monroe DG, Farr JN. . Sympathetic  $\beta$ 1-adrenergic signaling contributes to regulation of human bone metabolism. *J Clin Invest*. 2018 Nov 1;128(11):4832-4842. doi: 10.1172/JCI122151. Epub 2018 Oct 2.
298. Xi G, Wai C, **Rosen CJ**, Clemmons DR. . A peptide containing the receptor binding site of insulin-like growth factor binding protein-2 enhances bone mass in ovariectomized rats. *Bone Res*. 2018 Aug 14;6:23. doi: 10.1038/s41413-018-0024-9. eCollection 2018..
299. Carvalho AL, Massaro B, Silva LTPE, Salmon CEG, Fukada SY, Nogueira-Barbosa MH, Elias J Jr, Freitas MCF, Couri CEB, Oliveira MC, Simões BP, **Rosen CJ**, de Paula FJA. . Emerging Aspects of the Body Composition, Bone Marrow Adipose Tissue and Skeletal Phenotypes in Type 1 Diabetes Mellitus. *J Clin Densitom*. 2018 Jul 5. pii: S1094-6950(18)30072-6. doi: 10.1016/j.jocd.2018.06.007. [Epub ahead of print]
300. Woods GN, Ewing SK, Sigurdsson S, Kado DM, Ix JH, Hue TF, Eiriksdottir G, Xu K, Gudnason V, Lang TF, Vittinghoff E, Harris TB, **Rosen CJ**, Li X, Schwartz AV. Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity. *J Bone Miner Res*. 2018 Dec;33(12):2158-2164. doi: 10.1002/jbmr.3562. Epub 2018 Aug 27.
301. Ziru Li<sup>1</sup>, Julie Hardij<sup>1</sup>, Simon S. Evers<sup>2</sup>, Chelsea R. Hutch<sup>2</sup>, Sarah M. Choi<sup>3</sup>, Yikai Shao<sup>2</sup>, Brian S. Learman<sup>1</sup>, Kenneth T. Lewis<sup>1</sup>, Rebecca L. Schill<sup>1</sup>, Hiroyuki Mori<sup>1</sup>, Callie A.S. Corsa<sup>1</sup>, Devika P. Bagchi<sup>1</sup>, Steven M. Romanelli<sup>1</sup>, Ki-Suk Kim<sup>2</sup>, Cameron Griffin<sup>4</sup>, Randy J. Seeley<sup>2</sup>, Kanakadurga Singer<sup>4</sup>, Darleen A. Sandoval<sup>2</sup>, **Clifford J. Rosen**<sup>5</sup>, and Ormond A. MacDougald<sup>1</sup>. Mechanisms by which vertical sleeve gastrectomy influences bone and the marrow niche. *J Clin Investigation* 2019 In Press.

b) Peer Review Editorials, Perspectives from more than 180

1. Rosen CJ. 1994. Health Care Reform in the United States: Implications for the management of patients with metabolic bone diseases. *J Bone Min Res*; 9(5): 595-598.
2. Coulston AM and Rosen CJ. 1994. Federal Health Care Reform: Implications for Medical Nutrition Therapy. *Am J Clin Nutrition*; 59:1275-76.
3. Adler RA, and Rosen CJ. 1994. Glucocorticoids and osteoporosis. *Endocrinol Metab Clin North Am* 23:641-654.
4. Rosen CJ, Donahue LR, and Hunter SJ. 1994. Insulin-like growth factors and bone: the osteoporosis connection. *Proc Soc Exp Biol Med* 206:83-102.
5. Rosen CJ. 1994. Growth Hormone, Insulin-like Growth Factors and Senescent Bone: Revisiting Ponce de Leon's Fountain. *J Cell Biochem*; 58:1-9.
6. Rosen CJ. 1995. The role of bisphosphonates and fluorides in the prevention and treatment of osteoporosis. *Top Ger Rehab*; 10:19-34.

7. Rosen CJ and Donahue LR. 1995. Osteoporosis: Novel Treatment Strategies. *Drug News and Perspectives*; 8:89-96.
8. Rosen CJ and Donahue LR. 1995. IGFs: Potential Therapeutic Options for Osteoporosis. *Trends Endocrinol Metab*; 6:235-241.  
Miller PD, Bonnick SL, and Rosen C. 1995. Guidelines for the clinical utilization of bone mass measurement in the adult population. Society for Clinical Densitometry. *Calcif Tissue Int* 57:251-252.
9. Miller PD, Bonnick SL, and Rosen CJ. 1996. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. *Calcif Tissue Int* 58:207-214.
10. Miller PD, Bonnick SL, Rosen CJ, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsman AB, Kleerkoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NF, Raisz LG, Recker RR, Utian WH, Wasnich RD, Watts NB. 1996. Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. *Semin Arthritis Rheum* 25:361-372
11. Kessenich CR and Rosen CJ. 1996. Comparative Pharmacology and Clinical Utilization of the Bisphosphonates. *Drugs*; 51(4):537-551 42.
12. Kessenich CR and Rosen CJ. 1996. Osteoporosis in Men. *Geriatric Nursing*; 17:171-174.
13. Kessenich C and Rosen CJ. 1996. Vitamin D sufficiency in the elderly. *Orthoped Nursing*; 15 :67-71.
14. Millard PS, Rosen CJ and Thomas S. 1996. Playing With a Stacked Deck: How the Maine Health Care Reform Commission Dealt Bad Cards to a Single Payer Plan. *Maine Public Policy Review*; 5:33-38.
15. Rosen CJ and Kessenich C. 1996. The role of IGF-I in Senescence: Implications for Therapy. *The Endocrinologist*; 6:102-106.
16. Donahue LR and Rosen CJ. 1996. PTH and osteoporosis. *Current Opinions in Endocrinology*; 3:6:532-540. 47.
17. Kessenich CR and Rosen CJ. 1997. Risk Factors for Osteoporosis in Men. *Clin Geriatrics*; 5:87-96.
18. Rosen CJ and Kessenich CR. 1997. The pathophysiology and treatment of postmenopausal osteoporosis: an evidence based approach. *Clin Endocrinol Metab*. 26: 295-311.
19. Rosen CJ and Kessenich CR. 1997. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. *Bone Depeche*; 3:1:15-18.  
Rosen CJ, and Kessenich CR. 1997. The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. *Endocrinol Metab Clin North Am* 26:295-311.
20. Rosen CJ. 1997. Endocrine diseases and osteoporosis. *Current Opinions in Rheumatology*; 9:355-361.
21. Rosen CJ and Bilezikian JP. 1997. Evolving towards a new paradigm for prevention of osteoporosis: the time is upon us. *J Clin Endocrinol Metab*; 82:2782-2783.
22. Rosen CJ and Conover C. 1997 The growth hormone IGF axis in aging; a summary of an NIA symposium. *J Clin Endocrinol Metab*. 82:3919-3923.
23. Rosen CJ. 1997. Endocrine Disorders and osteoporosis. *Current Opinion in Orthopedics*; 8:38-44.
24. Rosen CJ. 1997. Prescribing etidronate for osteoporosis: a tale of two worlds. *Lancet*; 350:1340.
25. Rosen CJ. 1997. Biochemical markers of bone turnover in postmenopausal women. *Menopause Digest*; 2 19.
26. Rosen CJ. 1997. IGF-I and PTH: Future therapeutics for osteoporosis. *Exp Opin Invest Drugs* 6:1193-1198.
27. Rosen CJ. 1997. Growth hormone, IGF-I and the elderly: Clues to potential therapeutic intervention. *Endocrine*; 7:39-40.

28. Rogers J, Mahaney MC, Beamer WG, Donahue LR, and Rosen CJ. 1997. Beyond one gene-one disease: alternative strategies for deciphering genetic determinants of osteoporosis. *Calcif Tissue Int* 60:225-228.
29. Rosen CJ and Bilezikian JP. 1997. Evolving toward a new paradigm for prevention of osteoporosis--the time is upon us. *J Clin Endocrinol Metab* 82:2782-2783.
30. Rosen CJ. 1997. The Serum IGF regulatory system: Mirror or Mirage. Proceedings of the 2nd and 3rd Annual DSL International Scientific Meetings. DSL. Houston TX. pp 208-210.
31. Rosen CJ. 1998. Vitamin D: a review. *J Bone Min Res*; 13:280.
32. Mussavi M and Rosen CJ. 1998. The Skeletal Response to HRT: Results of a Meta-analysis in Menopause Management; 7:22-23.
33. Rackoff PJ and Rosen CJ. 1998. Epidemiology of glucocorticoid induced osteoporosis in the elderly. *Drugs and Aging*; 6:477-484.
34. Rosen CJ, Rackoff PJ, Pochenkova M and Barille D. Regulation of the IGF-I phenotype in Adults: potential heritable determinants. DSL 4th International Meeting; 1998;4:87-91.
35. Rackoff PJ, and Rosen CJ. 1998. Peripheral bone mass measurements: current and future perspectives on quantitative ultrasound and peripheral DXA. *J Clin Densitom* 1:287-294.
36. Rackoff PJ, and Rosen CJ. 1998. Pathogenesis and treatment of glucocorticoid-induced osteoporosis. *Drugs Aging* 12:477-484.
37. Rosen CJ. 1998. Pre-emptive bone strikes in prevention of osteoporosis. *Lancet* 351:927-928.
38. Rosen CJ, and Donahue LR. 1998. Insulin-like growth factors and bone: the osteoporosis connection revisited. *Proc Soc Exp Biol Med* 219:1-7.
39. Rosen CJ, Glowacki J, and Craig W. 1998. Sex steroids, the insulin-like growth factor regulatory system, and aging: implications for the management of older postmenopausal women. *J Nutr Health Aging* 2:39-44.
40. Rosen, C.J., and Rackoff, P.J. 1998. Ultrasound proves clinical usefulness in osteoporosis. *Diagn Imaging (San Franc)* Suppl Bone Mass:11-15.
41. Rosen CJ, Holick MF and Chen TC. 1998. Seasonal Bone Loss in Elderly Women: Pathogenesis and Potential Implications. Biologic Effects of Sunlight. DeGruyter.
42. Rosen CJ and Tenenhouse A. 1998 Biochemical Markers of Bone Turnover: Current and Future Clinical Perspectives. *Postgraduate Medicine*; 104:101-114.
43. Rosen CJ. 1999. Conflict of interest: explicit rules. *J Clin Densitometry*; 3:209-210.
44. Bilezikian JP, Kurland ES, and Rosen CJ. 1999. Male Skeletal Health and Osteoporosis. *Trends in Endocrinol Metab*; 8:244-250.
45. Rosen CJ and Bilezikian JP. 1999. Perplexing polymorphisms: DIPS SNIPS and TRIPs. *J Clin Endocrinol Metab*; 84:4465-66.
46. Rosen CJ. 1999; Serum IGF-I and IGF binding proteins: Clinical Implications. *Clin Chem*; 45:1384-1390.
47. Rosen CJ and Pollak MF. 1999. IGF-I and Aging: A New Perspective for a New Century. *Trends in Endocrinol Metab*; 10: 136-142.
48. Crawford-Sharpe G and Rosen CJ. 1999. IGF-I and the Skeleton: New Perspectives. *The Endocrinologist*; 9:81-86.
49. Rosen CJ. 1999. Conflict of interest: explicit rules! *J Clin Densitom* 2:209-210.
50. Rosen CJ. 1999. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. *Clin Chem* 45:1384-1390.
51. Rosen CJ, and Bilezikian JP. 1999. Perplexing polymorphisms: D(i)ps, Sn(i)ps, and trips. *J Clin Endocrinol Metab* 84:4465-4466.
52. Rosen CJ. 2000. Pathogenesis of Osteoporosis. *Clin Endocrinol Metab*; 14: 2: 181-193.
53. Rosen CJ. 2000. Pathophysiology of Osteoporosis. *Clinics in Laboratory Medicine*; 20;455-468.
54. Rosen CJ. 2000. IGF-I in Osteoporosis. *Clinics in Laboratory Medicine*; 20:591-602.
55. Rosen CJ. 2000. SERMS and Bone: Menopause Management. 9:23-26.
56. Rosen CJ. 2000. Fluoride and Fractures: An Ecologic Fallacy. *Lancet*; 355:247-248.
57. Beamer WG, Donahue LR and Rosen CJ. 2000. IGF-I and Bone: from mouse to man. *Growth Hormone and IGF Res*; 6:S103-105.

58. Crawford GC and Rosen CJ. 2000. Bone density in the management of Turner syndrome. Proceedings for the 5th International Turner Symposium-Optimizing Health Care for Turner Patients in the 21st Century Ed by P Saenger and Paquino. Elsevier-London BI. pp 263-265.
59. Rosen CJ. 2000. Growth hormone and Aging. *Endocrine*; 12:197-201.
60. Greenspan SL, Harris ST, Miller PD, Orwoll ES, Watts NB and Rosen CJ. 2000. Bisphosphonates: Safety and Efficacy in the Treatment and Prevention of Postmenopausal Osteoporosis. *Am Family Physician*; 61:2731-2736.
61. Rosen CJ. 2000. Estrogens and SERMs: Mechanisms of Action and Role in the Prevention and Treatment of Osteoporosis. *Resident and Staff Physician*; 46; 10-16.
62. Rosen CJ and Rackoff PJ. Emerging Anabolic Treatments for Osteoporosis. *Rheum Clinic North America*; Ed by N Lane. 2001; 27: 215-235.
63. Rosen CJ and Bilezikian JP. 2001. Hot topics in Endocrinology: Anabolic Therapy in Osteoporosis. *J Clin Endocrinol Metab*; 86: 957-964.
64. Rosen CJ, Donahue LR, and Beamer WG. 2001. Defining the genetics of osteoporosis: using the mouse to understand man. *Osteoporosis Int*; 12:803-810.
65. Rosen CJ. 2001. Treatment of postmenopausal osteoporosis: an evidence based approach. *Reviews in Endocrine and Metab Disorders*; 2: 35-43.
66. Chesnut CH, Lyles KW, Rosen CJ. 2001. Bone quality: enhancing the clinician's understanding of anti-resorptive therapies. *Clinical Geriatrics*.
67. Rosen CJ. 2001. Treatment of postmenopausal osteoporosis: an evidence-based approach. *Rev Endocr Metab Disord* 2:35-43.
68. Rosen CJ, Beamer WG, and Donahue LR. 2001. Defining the genetics of osteoporosis: using the mouse to understand man. *Osteoporosis Int* 12:803-810.
69. Rosen CJ, and Bilezikian JP. 2001. Clinical review 123: Anabolic therapy for osteoporosis. *J Clin Endocrinol Metab* 86:957-964.
70. Rosen CJ, and Rackoff PJ. 2001. Emerging anabolic treatments for osteoporosis. *Rheum Dis Clin North Am* 27:215-233, viii.
71. Rosen CJ. 2001. The Insulin like growth factor system and bone. *Curr Opin Endocrinol Diabetes*; 8:271-282.
72. Chesnut CH, Rosen CJ. 2001. Reconsidering the effects of anti-resorptive therapies in reducing osteoporotic fracture. *J Bone Min Res*; 16: 2163-2173.
73. Yakar S, Wu Y, Setser J, and Rosen CJ. 2002. The role of circulating IGF-I: lessons from human and animal models. *Endocrine* 19:239-248.
74. Yakar S and Rosen CJ. 2002. The role of circulating IGF-I. *Endocrine*; 19: 239-248.
75. Cranney A, Guyatt G, Wells G, Tugwell P, Rosen C (Chair). 2002. Meta Analysis of Therapies for Postmenopausal Osteoporosis. *Endocrine Reviews*; 4:495-570.
76. Rosen CJ. 2002. Add backs to prevent skeletal fragility: foresight or folly? *Menopause*. 9(4):224-6.
77. Beamer WG, Donahue LR, and Rosen CJ. 2002. Genetics and bone. Using the mouse to understand man. *J Musculoskelet Neuronal Interact* 2:225-231.
78. Rosen CJ. 2003. IGF-I and Calcium: Evolving aspects of an evolutionary process. *Endocrinology* 144:4679-4681.
79. Rosen CJ. 2003. PTH analogues for the treatment of osteoporosis. Harrison's Textbook of Medicine ON LINE.
80. Rosen, CJ. 2003. The Cellular and Clinical Parameters of Anabolic Therapy for Osteoporosis. *Critical Reviews in Eukaryotic Gene Expression*. 13(1):35-48.
81. Brown SA and Rosen CJ. 2003. Osteoporosis. *Med Clin N America*; 87: 1039-1063.
82. Yakar S., Rosen CJ 2003. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. *Exp Biol Med*; 228 (3):245-52.
83. Brown SA, and Rosen CJ. 2003. Osteoporosis. *Med Clin North Am* 87:1039-1063.
84. Rosen CJ. 2003. Restoring aging bones. *Sci Am* 288:70-77.
85. Rosen CJ, and Brown S. 2003. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. *N Engl J Med* 348:1503-1504.

86. Rosen CJ, and Wuster C. 2003. Growth hormone rising: did we quit too quickly? *J Bone Miner Res* 18:406-409.
87. Rosen CJ. 2003. Restoring aging bones. *Scientific American*; 288(3):70-77.
88. Rosen CJ. 2004. Nutrition and Bone Health in the Elderly. *Clinical Reviews in Bone and Mineral Metabolism*.
89. Rosen CJ. 2004. What's new with PTH in osteoporosis: Where we are and where are we going. *Trends in Endocrinol Metab*; 15:229-33.
90. Rosen CJ, Black DM, and Greenspan SL. 2004. Vignettes in osteoporosis: a road map to successful therapeutics. *J Bone Miner Res* 19:3-10.
91. Rosen CJ. 2004. Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. *Best Pract Res Clin Endocrinol Metab* 18:423-435.
92. Rosen CJ. 2004. What's new with PTH in osteoporosis: where are we and where are we headed? *Trends Endocrinol Metab* 15:229-233.
93. Colbert LH, Rosen CJ, Goodpaster BH, Newman AB, Kritchevsky SB, Satterfield S, Kanaya AM, Taaffe DR, Harris TB. 2004. Letter to the Editor regarding insulin-like growth factor-I. *J Aging Geriatrics*.
94. Rosen CJ and Brown SA. 2005. A Rationale Approach to Evidence Gaps in the Management of Osteoporosis. *Am J Med*. 118: 1183-1190.
95. Rosen CJ and Niu T. 2005. The IGF-I Gene and Osteoporosis: A Critical Re appraisal: *GENE*. 361: 38-56.
96. Rosen CJ. 2005. Medical Letter: Treatment of Osteoporosis.
97. Rosen CJ. 2005. The role of parathyroid hormone in the management of osteoporosis. *Horm Res* 64 Suppl 2:81-85.
98. Rosen CJ. 2005. Clinical practice. Postmenopausal osteoporosis. *N Engl J Med* 353:595-603.
99. Ackert-Bicknell C, and Rosen C. 2006. The Genetics of PPAR $\gamma$  and the Skeleton. *PPAR Res* 2006.
100. Rosen CJ, and Boussein ML. 2006. Mechanisms of disease: is osteoporosis the obesity of bone? *Nat Clin Pract Rheumatol* 2:35-43.
101. Rosen CJ. 2007. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. *N Engl J Med* 357:844-846.
102. Rosen CJ. 2007. Mouse models for understanding the growth hormone insulin-like growth factor-I axis. *Horm Res* 68 Suppl 5:2-4.
103. Black DM, and Rosen CJ. 2007. Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? *Nat Clin Pract Rheumatol* 3:378-379.
104. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. 2008. Marrow Fat and the Bone Micro-environment: Developmental, Functional, and Pathological Implications. *Crit Rev Eukaryot Gene Expr*. NIHMS 77529
105. Rosen CJ. 2008. Bone remodeling, energy metabolism, and the molecular clock. *Cell Metab* 7:7-10.
106. Rosen CJ. 2008. Sugar and Bone: A Not-So Sweet Story. *J Bone Miner Res* 12:1881-3. PMC2587525
107. Kawai M, and Rosen CJ. 2009. Insulin-like growth factor-I and bone: lessons from mice and men. *Pediatr Nephrol* 24(7):1277-85.
108. Rosen CJ, and Klibanski A. 2009. Bone, Fat, and Body Composition: Evolving Concepts in the pathogenesis of Osteoporosis. *Am J Med* 122:409-414. PMC Journal - In Process
109. Rosen CJ. 2009. Bone: serotonin, leptin and the central control of bone remodeling. *Nat Rev Rheumatol* 5:657-658.
110. Rosen CJ. 2009. Breaking into bone biology. Serotonin's secrets. *Nat Med* 15:145-146.
111. Rosen CJ. 2009. Serotonin Rising -- The Bone, Brain, Bowel Connection. *N Engl J Med* 360(10):957-9.
112. Kawai M, Devlin MJ, Rosen CJ. 2009. Fat targets for skeletal health. *Nat Rev Rheumatol* 5(7):365-72. PMC Journal - In Process

113. Ackert-Bicknell CL, Rosen CJ. The future of mouse genetics in osteoporosis research. *IBMS BoneKEy*. 2009 June;6(6):2009.
114. Rosen CJ. 2009. Leptin's RIGHT turn to the brain stem. *Cell Metab* 10(4):243-4. PMC Journal - In Process
115. Kawai M and Rosen CJ. PPAR $\gamma$ : a circadian transcription factor in adipogenesis and osteogenesis. 2010 *Nat Rev Endocrinol* Sept 7 Epub ahead of print-IF:6.4
116. Rosen CJ. Revisiting the rosiglitazone story – lessons learned *N Engl J Med* 2010 363:803-806 IF:52
117. Kawai M and Rosen CJ. Mini review: A skeleton in serotonin's closet. 2010 *Endocrinology* 151:4103-4108 IF:4.9.
118. Rosen CJ and Motyl KJ. No bones about it: insulin modulates skeletal remodeling. 2010 *Cell* 142 198-200. IF: 18.
119. Kawai M and Rosen CJ. The IGF regulatory system and its impact on skeletal and energy homeostasis. *J Cell Biochem* 2010 111:14-19. IF:3.0.
120. Rosen CJ. Exploiting new targets for old bones. *J Bone Miner Res* 2010: 25:934-936.
121. Kawai M, Sousa KM, MacDougald OA and Rosen CJ. The many facets of PPAR $\gamma$ : novel insights for the skeleton. *Am J Physiol Endocrinol Metab* 2010: 299: E3-E9. IF3.2
122. Rosen CJ and Khosla S. Placebo-Controlled Trials in Osteoporosis – Proceeding with Caution; *N Engl J Med* 2010:363:14 epub ahead of print Sept 29, 2010.
123. Lecka-Czernik B, Rosen CJ and Kawai M. Skeletal aging and the adipocyte program: New insights from an 'old' molecule: *Cell Cycle* 2010 in press IF:4.8.
124. Kawai M, and Rosen CJ. Bone: adiposity and bone accrual-still an established paradigm? *Nat Rev Endocrinol* 2010 6:63-64.
125. de Paula FJ, and Rosen CJ. Developing drugs to treat osteoporosis: lessons learned? *Expert Opin Pharmacother* 2010; 11:867-869.
126. Rosen CJ. Vitamin D insufficiency. *N Engl J Med* 2011;364: 248-254
127. Kawai M, Mödder UI, Khosla S, Rosen CJ. 2011 Emerging therapeutic opportunities for skeletal restoration. *Nature Reviews Drug Discovery* 10:141-156.
128. Farber C and Rosen CJ. Genetics of Osteoporosis. *Translational Endocrinology and Metabolism*, 2010. 87-116.
129. Rosen CJ and Gallagher JC. The 2011 IOM report on vitamin D and calcium: clinical implications for providers treating patients with low bone mineral density. *J Clin Densitom* 2011 14: 79-84.
130. Motyl KJ, Rosen CJ. Temperatures rising: brown fat and bone. *Discovery Med* 2011; 11: 179-185
131. Gallagher JC and Rosen CJ. The Institute of Medicine Responds. *BMJ* 2011;342:4046
132. dePaula FJ and Rosen CJ. Vitamin D Requirements and Safety *Arch Biochem and Biophys* 2011 Epub ahead print
133. Rosen CJ Vitamin D and falls- are intermittent high doses better? *Nat Rev Endocrinol* 2011 7: 695-696.
134. Kawai M, dePaula FJ, Rosen CJ. New Insights into osteoporosis: the bone-fat connection. *J Int Med* 2012;27:317-29.
135. Motyl KJ, Rosen CJ. The Skeleton and the Sympathetic Nervous System: It's about Time! *J Clin Endocrinol Metab*. 2012 Nov;97(11):3908-11. doi: 10.1210/jc.2012-3205. No abstract available
136. Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS, Rosen CJ and Klibanski A. Marrow Fat and Bone- New Perspectives *J Clin Endocrinol Metab* 2013 In Press
137. Motyl KJ and Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis *Biochimie* 2012 94:2089-96.
138. Guntur AR and Rosen CJ. Bone as an endocrine organ. *Endocr Pract*. 2012: 5:758-762.
139. Kawai M, Rosen CJ. The IGF system in bone: basic and clinical implications. *Endocrinol Metab clin North Am* 2012:41:323-33.
140. Rosen CJ Building bones by knocking down genes. *Nat Med* 2012: 18: 202-204
141. Black DM and Rosen CJ. Following the bone density trail: a clinical perspective. *J Clin Endocrinol Metab* 2012:97: 1176-1178.



142. Rosen CJ, Mayne ST. IOM Committee on DRI for Vitamin D and Calcium: Vitamin D dose requirements for fracture prevention: N Engl J Med 2012;367:1368.
143. Rosen CJ and Taylor CL. Common Misconceptions about Vitamin D: Implications for Clinicians. Nature Rev Endocrinol 2013 In Press
144. Rosen CJ. Vitamin D: Bones of Contention. Lancet 2013 IN PRESS Oct 10,201
145. Schmidt TA, **Rosen CJ**, Yudkin JS. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin. BMJ. 2013 Jun 11;346:f3731. doi: 10.1136/bmj.f3731.
146. Rosen CJ. Bones of Contention. Lancet Oct 11,2013 OnLineFirst Jan 2014
147. Rosen CJ and Ingelfinger JR. Unraveling the function of FTO Variants. N Engl J Med 2015:964-5
148. Lecka-Czernik B, Rosen CJ. Skeletal integration of energy homeostasis: Translational implications. Bone. 2015 Jul 23. pii: S8756-3282
149. Shanbhogue VV, Mitchell DM, Rosen CJ, Bouxsein ML. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2015 Sep 10. pii: S2213-8587
150. Lecka-Czernik B, Rosen CJ. Energy Excess, Glucose Utilization, and Skeletal Remodeling: New Insights. J Bone Miner Res. 2015 Aug;30(8):1356-61
152. Reagan MR, Rosen CJ. Navigating the bone marrow niche: translational insights and cancer driven dysfunction. Nat Rev Rheumatol 2015 Nov 26 Epub
153. Hardouin P, Marie PJ and Rosen CJ. New insights into bone marrow adipocytes: report from the first European meeting on bone marrow adiposity. Bone 2015 Nov 30 Epub ahead of print.
154. Ackert-Bicknell CL and Rosen CJ. Passenger Gene Mutations: Unwanted Guests in Genetically Modified Mice. J Bone Miner Res 2015 Dec 18 epub ahead of print
155. Ingelfinger JR and Rosen CJ. Cardiovascular risk and sodium-glucose co-transporter 2 inhibition in type 2 diabetes. N Engl J Med 2015 373: 2178-79
156. Black DM and Rosen CJ. Clinical Practice: Postmenopausal Osteoporosis. N Engl J Med 2016;374: 254-62
157. Suchacki KJ, Cawthon WP, and Rosen CJ. Bone marrow adipose tissue: formation, function and regulation. Curr Opin Pharmacol 2016 28: 50-56.
158. Fairfield H, Rosen CJ, ReaganMR. Connecting Bone and Fat: the Potential Role of Sclerostin
159. Rosen CJ and Zaidi M. Contemporaneous reproduction of preclinical science. Ann NY Acad Sci 2017 Sep 1404 17-19
160. Oxburgh L and Rosen CJ. New Insights into Fuel Choices of Nephron Progenitor Cells. J Am Soc Nephrol 2017 Sep 5
161. Rosen CJ. Romosozumab- Promising or Practice Changing? N Engl J Med 2017 Oct 12, 377 1479-1480.
162. Lee WC, Guntur AR, Long F and Rosen CJ. Energy Metabolism of the Osteoblast: Implications for Osteoporosis. ENdochr Rev 2017: 38: 255-266.
163. Reagan MR, Lian JB, Rosen CJ and Stein GS. A perspective on malignancy in the marrow. J Cell Physiol 2017 De: 232: 3218-3220
164. Rendina-RUedy E and Rosen CJ. Bone-Fat Interactions: Endocrinol Metab Clin North Am; 2017: 46: 41-50.
165. Veldhuis-Vlug AG, **Rosen CJ** [Clinical implications of bone marrow adiposity..](#) J Intern Med. 2018 Feb;283(2):121-139

#### **BOOKS, CHAPTERS, AND SPECIAL EDITIONS** (From more than 34 books and chapters)

1. Rosen CJ and Baran DT. Thyroid Hormone and Bone Metabolism. Eds. by LE Braverman, Boots Flint Inc.Lincolnshire,Ill. 1992; pp 13-17.
2. Rosen CJ and Wuster C. Growth Hormone, Insulin-like growth factors: Potential applications and limitations in the management of osteoporosis. Osteoporosis eds by Feldman DW, Marcus R and Kelsey J. Academic Press, San Diego CA 1996; 69:1313-1333.
3. Osteoporosis: Diagnostic and Therapeutic Principles ed by Rosen CJ. Humana Press 1996. Chapters 3,11,18.Towana,NJ.
4. Rosen CJ. Osteoporosis; in Current Therapy. eds by J. Snyder; 9th Edition 1996 pp 1168-1174.

5. Rosen CJ and Johannsson A. IGFs for the Treatment of Osteoporosis in Principles of Bone Biology, 1996 eds by J. Bilezikian, L. Raisz and G. Rodan, Academic Press. San Diego CA pp 1099-11.
6. Rosen CJ. IGF-I and its anabolic activity in bone. in Anabolic Treatments in Osteoporosis ed by Whitfield F. CRC Press. 1997; Boca Raton FL pp 185-205.
7. Rosen CJ. Heart and Endocrine Diseases in Current Practice of Medicine, ed 2; by Roger Bone and Faith Fitzgerald. Current Science Group, Philadelphia PA; 36:1-8; 1997.
8. Rosen CJ and Conover C (Eds). Growth hormone and IGF-I in aging: A Symposium. Endocrine 1997; 7:39-125.
9. Compston JE and Rosen CJ. Osteoporosis: Fast Facts. Editions I, II, III Health Press, Oxford, England 1997-2002.
10. Rosen CJ. Vitamin D in Bone Health in Vitamin D: Basic Biology and Application ed by MF Holick, Humana Press, 1998; pp 287-307
11. Rosen CJ. Age-related osteoporosis in Cartilage and Bone Metabolism. Eds by Seibel M and Bilezikian JP. Academic Press, 1998 Books, Book Chapters and Special Editions pp 479-492
12. Bilezikian JP, Kurland ES and Rosen CJ. Idiopathic osteoporosis in Men in Osteoporosis in Men; ed by E Orwoll. Academic Press, 1998.
13. Donahue LR and Rosen CJ. GH and IGF-I therapy in the elderly. In the Aging Skeleton. ed by Rosen CJ, Bilezikian JP and Glowacki J. Academic Press 1999.
14. Rosen CJ, Bilezikian JP and Glowacki J. Eds The Aging Skeleton. In Press 1999. Academic Press, San Diego CA.
15. Rosen CJ. IGF-I in Men. In Osteoporosis in Men, ed by E Orwoll. Academic Press, 1999.
16. Rosen CJ. Bone Anabolic Agents. In Atlas of Clinical Endocrinology. Ed by Korenman S. 2000 Current Medicine, Philadelphia Medicine, 169-179.
17. Rosen CJ. Insulin like growth factors: clinical aspects. In Growth Factors and the Skeleton. Ed by Canalis E. Lippincott Press 2000. Pp 117-129.
18. Rosen CJ. Guest Editor: Clinics in Laboratory Medicine: Osteoporosis. 2000.
19. Rosen CJ. The Genetics of Osteoporosis. In the Osteoporotic Syndrome Ed by Avioli LV; Academic 2000, San Diego CA; pp 37-45.
20. Rosen CJ. The Growth Hormone IGF-I Axis and Menopause. In Menopause: Biology and Pathobiology ed by Lobo RE, Kelsey J and Marcus R. Academic Press 2000 San Diego CA, 271-282.
21. Rosen CJ. Endocrine Disease and the Heart. In Cardiology for the Primary Care Physician ed I and II by J Alpert. 2001, 2004.
22. Rosen CJ. Osteoporosis Pathophysiology and Epidemiology. In Endotext.com Textbook of Endocrinology; ed by DeGroot LJ. 2002, www.Endotext.org.
23. Conover CA and Rosen CJ. IGFs and Bone. In Principles of Bone Biology 2002, 2007; ed by Bilezikian JP, Raisz L, and Rodan G. Academic Press 2002, San Diego CA. Pp 801-827.
24. Rosen CJ. IGF-I and Bone Mineral Density: Experience from animal models and human observational studies. Best's Endocrinology 2004.
25. Rosen CJ. Osteoporosis in Current Therapy 2005.
26. Rosen CJ and Brown S. Osteoporosis and Bone in Evidence Based Endocrine Practice. 2005 Eds by Montori V
27. Rosen CJ. Osteoporosis. In Cecil and Loeb Textbook of Medicine 2006. Chapter 258.
28. Rosen CJ, Marcus R, Feldman D and Nelson D. Osteoporosis. Academic Press 2007.
29. Rosen CJ and Compston JE. Fast facts in osteoporosis. 5th edition. London Health Press, 2007
30. Rosen CJ and Niu T. Insulin-like Growth Factors and the IGF Binding Proteins: Implications for Bone Biology. In Principles of Bone Biology, Third Edition. 2008.
31. dePaula F and Rosen CJ. Osteoporosis: Conn's Current Therapy 2011, Elsevier San Diego Ca 627-632.
32. Rosen CJ. Osteoporosis. Chapter 251, Cecil and Loeb Textbook of Medicine ed by L Goldman. 2011.

33. Urs SK and Rosen CJ. Diseases of Energy and Lipid Metabolism and Bone: Emerging Therapeutics. In Bone-Metabolic Functions and Modulators, ed by Bronner F, Farach-Carson MC, Roach H. Springer, New York, 2013.pp 133-146.
34. Melov S and Rosen CJ. Advances in Geroscience: Musculoskeletal Aging. 2015 edited by Sierra F, Springer.

Editor: Principles of Bone Biology 4<sup>th</sup> Edition- Rosen CJ, Clemens TL, Biliezikian J, and Martin TJ  
 Editor: Williams 14<sup>th</sup> Edition Textbook of Endocrinology- Melmed S, Rosen CJ, Koenig R, Goldfine A.

### **AD HOC JOURNAL REVIEWER**

American Journal of Clinical Nutrition  
 American Journal of Managed Care  
 American Journal of Medicine  
 American Journal of Obstetrics and Gynecology  
 American Journal of Physiology  
 Bone  
 Drugs  
 Endocrinology  
 Growth Development and Aging  
 Growth Regulation  
 Hormone and Metabolic Research  
 Journal of the American Medical Association  
 Journal of Cellular Biochemistry  
 Journal of Clinical Investigation  
 Journal of Endocrinology  
 Journal of Experimental Medicine  
 Journal of FASEB  
 Journal of Gerontology  
 Journal of Women's Health  
 Kidney International  
 Lancet  
 Metabolism  
 Nature  
 Nature Medicine  
 New England Journal of Medicine  
 Osteoporosis International  
 Science  
 Plastic Reconstructive Surgery  
 PLOS Genetics  
 PLOS1  
 Primary Care Reports  
 Proceedings of the National Academy of Science

### **SELECTED EARLY PEER-REVIEWED PUBLISHED ABSTRACTS** (out of more than 1000)

1. Eastman RC, Bigos TL and Rosen CJ. 1985 "Papillary Thyroid Cancer in an Endocrine Practice." 67<sup>th</sup> Endocrine Society, #624, Baltimore, MD.
2. Rosen CJ, Rosenthal B, and Andrews RC. 1986 "Bone Loss in Hyperthyroidism Measured by Dual Photon Absorptiometry." Maine Biologic Symposium, June.
3. Rosen CJ, and Adler RA. 1987 "Prolactin Levels Predict Bone Mineral Content in Hyperprolactinemia Women." 68<sup>th</sup> Endocrine Society#406 June, Indianapolis, Indiana.
4. Rosen CJ, Owens MA and Adler RA. 1987 "Altered Lymphocyte Subsets in Post Menopausal Osteoporosis." American Society of Bone Mineral Research. Indianapolis, Indiana, September.

5. Davee AM, Rosen CJ. 1988 "Determinants of Vertebral Bone Density in Eumenorrhic College Women." American Dietetic Association, San Francisco, October, 71<sup>st</sup> Annual Meeting.
6. Sherblom AS, Rosen CJ. 1989 "Uromodulin Mediated Clearance of IL-1 in Osteopenia." FASEB, #3531, New Orleans, LA.
7. Donahue LR, Russell SJ, Smith-Porter E, and Rosen CJ. 1989 "Concentrations of Circulating IGF-I in the Elderly." 71<sup>st</sup> Meeting, The Endocrine Society, #380, Seattle, WA.
8. Rosen CJ and Adler RA. 1989 "Longitudinal Evaluation of Lumbar Spine Absorptiometry in Normal Post-Menopausal Women", AFRCR, #460A.
9. Donahue LR, and Rosen CJ. 1989 "Serum Low Molecular Weight Insulin-like Growth Factor Binding Protein in Type II Osteoporosis", ASBMR, #128.
10. Donahue LR and Rosen CJ. 1990 "Age-Related Changes in Serum Insulin Like Growth-Factor Binding Proteins in Women" 72<sup>nd</sup> Annual Meeting Endocrine Society, Atlanta, GA.
11. Donahue LR and Rosen CJ. 1990 "Anorexia, Hypoglycemia, and the 30K Low Molecular Weight IGF-Binding Protein" 72<sup>nd</sup> Annual Meeting Endocrine Society, Atlanta, GA.
12. Donahue LR, Rosen CJ Spindler AA and Renvall M. 1990 "Increased IGF-I concentrations in institutionalized women with Alzheimer's disease." *Neurobiology of Aging* 11:3,256.
13. Rosen CJ 1990 "Acute Hemarthrosis as a Presentation of Primary Hyperparathyroidism." *J Bone Min Res* 5 Supp 2, #277.
14. Rosen CJ, Hunter S, Musgrave KO, Bing-You R. 1990 "A three year study of lumbar BMD and calcium intake in early postmenopausal women without estrogen therapy." *J Bone Min Res* 5:#2:140a.
15. Rosen CJ, Hunter SJ, Adler RA. 1991 "Cyclic Etidronate and type II osteoporosis." *J Bone Min Res* 6:#1 785a.
16. Rosen CJ, Donahue LR, Ramsdell J, Spindler AA, Renvall M and Nichols J. 1991 "Evidence for Alteration in the GH, IGF-I Axis of Alzheimer's Patients." International Somatomedin Meeting, #299, California.
17. Simone K, Rosen CJ, Stene M. 1991 "Relationship of endogenous and exogenous sex steroids to circulating IGF-I and IGFBP-3 in postmenopausal women." International Somatomedin Meeting, #58, California.
18. Mohan S, LaTour D, Linkhart T, Rosen CJ, Baylink DJ and Strong DD. 1991 "Evidence that PTH increases the production of inhibitory IGFBP at the protein and mRNA levels in HBCs by a cyclic AMP dependent mechanism." International Somatomedin Meeting, California, #58.
19. Rosen CJ, and Baylink DJ. 1991 "Hypercalcemia associated with Adrenal Insufficiency." *J Bone Min Res* 6 Supp 1, (Boy Frame Abstract).
20. Hunter SJ, Peters LL, Higgins A, Wood BG, and Rosen CJ. 1991 "Light Microscope Level Immunocytochemical Localization of Ankyrin and Spectrin in Chick Osteoclasts." *J Bone Min Res* 6 Supp 1,#271.
21. Linnel P, Hermansen SJ, Elias M, Robbins M, Bing-You R, Kiel and Rosen CJ. 1991 "Quality of Life in Osteoporotic Women." *J Bone Min Res* 6 Supp 1 #96.
22. Rosen CJ, Donahue LR, Stene, M.,Hodsman A, Fraher LJ, Mohan S and Baylink D. 1991 "Pulsatile vs. Sustained Hyperparathyroidism on the Serum IGF regulatory system." *J Bone Min Res* 6 Supp 1, #812.
23. Rosen C and Morrison T. 1991 "Regulation of 1L-6 production by 1,25 vitamin D in skin fibroblasts." 17<sup>th</sup> Annual Maine Biologic Sciences Symposium.
24. Donahue LR, Rosen CJ and Beamer WG. 1991 "Comparison of IGFBPs in sera from normal and genetically small mice." 2<sup>nd</sup> Internat Somatomedin Mtg.#260.
25. Morrison T, Storm D, Chen T, Holick M Carlton E, and Rosen CJ. 1992 "Exercise Induced Changes in IGF-1 and Osteocalcin in rural elderly women." 74<sup>th</sup> Endocrine Society Meeting, #1112.
26. Rosen CJ, Hunter SJ, Zhao HP, Storm DS, Holick M, Chen T. 1992 "Seasonal changes in bone mass and biochemical markers in elderly rural women" *J Bone Min Research* 8;S#1 324.
27. Rosen CJ, Morrison AM, Fraher LJ, Hodsman A. 1993 "In vivo regulation of the GH-IGF-I Axis by PTH." *Calcified Tissue Int* 52:S#2

28. Morrison T, Storm D, Zhou H, Rosen C. 1993 "IGFBP profiles predict bone turnover and exercise induced GH changes in elderly women." 75th Endocrine Society #687
29. Stock JL, Rosen CJ, Shewmon DA, Morrison T, Heiniluoma KM, Coderre JA. 1993 "Effects of Estrogen and Tamoxifen on IGF-I and IGFBP-3 in healthy postmenopausal women." 75th Endocrine Society :1327
30. Shewmon D, Stock JL, Rosen CJ et al. 1993 "Serum IGF-I correlates with changes in Lp(a) during treatment with estrogen and tamoxifen." Circulation S#1.
31. Shewmon D, Roy V, Heiniluoma K, Hogue M, Rosen C and Morrison T. 1993 "Niacin therapy decreases serum concentration of IGF-I in parallel with those of lipoprotein (a).GHRH,GH and IGF-I: Basic and Clinical Advances." Sero Symposium, San Diego CA.
32. Plymate SR, Rosen CJ, Paulsen CA and Birnbaum RA. 1994 "Insulin-like growth factor binding protein measurements in seminal fluid." AFCR-Western Meeting, Clin Res 42:20A.
33. Rosen CJ, Holick MF. 1994 "Premature Graying of Hair May be a Risk Factor for Osteopenia." Endocrine Society 77th Session, Anaheim CA.
34. Rosen CJ, Bilezikian J and Hodsman AM. 1994 "Effects of Parathyroid Hormone on IGF-I and IGFBPs." Endocrine Society 77th Session, Anaheim CA.
35. Donahue LR, Rosen CJ and Beamer WG. 1994 "Reduced bone density in hypogonadal mice." J Bone Min Res 9S1 A 244.
36. Dalsky GP, Rosen CJ, Fenster JR, Biskup BG, Vereault D. 1994 "Serum IGF-I and body composition in older men and women." J Bone Min Res 9:S1;A342.
37. Zhou H, Putzi M, Rosen CJ, Hunter SJ. 1994 "Development of Chick Osteoclasts from Embryonic Bone Marrow." J Bone Min Res 9 S1.
38. Rosen CJ, Kiel DP, MacLean DB. 1994 "Serum IGF-I and its relationship to bone mass in frail elders." J Bone Min Res 9:S1 C242.
39. Kessenich CR and Rosen CJ. 1995 "Vitamin D Sufficiency in elderly osteoporotic women: Time Dose and Geographic Effects." Endocrine Society P2-622.
40. Rosen CJ, Steffens C, LeBoff M and Glowacki J. 1995 "Effects of age on the skeletal IGF regulatory system." Endocrine Society P3-676.
41. Rosen CJ, Vereault DV, Steffens C, Chen TC, Hunter SJ, Holick MF, Mohan S, Baylink DJ. 1995 "Mechanisms Responsible for Seasonal Bone loss in Elderly Women." J Bone Min Res 10;S 476.
42. MacLean DB, Kiel DP, and Rosen CJ. 1995 "Low dose GH for frail elders stimulates bone turnover in a dose-dependent manner." J Bone Min Res 10:S458.
43. Rosen CJ, MacLean DB and Kiel DP. 1996 "GH stimulates bone turnover and bone loss in a dose-dependent manner." Endocrine Society 78th Annual Meeting

*i) Invited lectures (last 3 years only)Selected*

March 2015-	Invited speaker- Pediatric Endocrine Society- San Diego Ca
March 2015-	Society of Toxicology- San Diego Ca.
April 2015	Israel Endocrine Society- Ashkelon, Il.
May 2015-	Invited Speaker- AACE annual meeting
December 2015	Dutch Endocrine Society- Amsterdam, Holland
February 2016	Speaker Invite: Keystone Adipose Meeting
February 2016	Gordon Conference Bone and Teeth
April 1, 2016	100 <sup>th</sup> Annual Endocrine Society
Feb 10,2017	GIGS Seminar- NIA
February2,2017	MUSC-Grand Rounds Charleston SC
March 2017	Grand Rounds UT Southwestern- Vitamin D- Whats New
April 2, 2017	Endocrine Society - Where are we in Osteoporosis Medicine
January 10,2018	UCSD- Medical Grand Rounds
November 14,2017	Medical College of Georgia- August- Grand Rounds
January 2018-	Gordon Conference- Bones and Teeth
February 2019	Keystone Obesity Meeting- Moderator
February 2019	Visiting Distinguished Professor- Virginia Polytechnic Institute-Medical School

*am*

October 16, 2020